<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">79747</article-id><article-id pub-id-type="doi">10.7554/eLife.79747</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>Inhibition of mutant RAS-RAF interaction by mimicking structural and dynamic properties of phosphorylated RAS</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-277681"><name><surname>Ilter</surname><given-names>Metehan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="pa1">‡</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-277682"><name><surname>Kasmer</surname><given-names>Ramazan</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-277683"><name><surname>Jalalypour</surname><given-names>Farzaneh</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="pa2">§</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-275074"><name><surname>Atilgan</surname><given-names>Canan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0557-6044</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-277684"><name><surname>Topcu</surname><given-names>Ozan</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-277685"><name><surname>Karakas</surname><given-names>Nihal</given-names></name><email>nkarakas@medipol.edu.tr</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-277686"><name><surname>Sensoy</surname><given-names>Ozge</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5950-3436</contrib-id><email>osensoy@medipol.edu.tr</email><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/037jwzz50</institution-id><institution>Graduate School of Engineering and Natural Sciences, Istanbul Medipol University</institution></institution-wrap><addr-line><named-content content-type="city">Istanbul</named-content></addr-line><country>Turkey</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/037jwzz50</institution-id><institution>Medical Biology and Genetics Program, Graduate School for Health Sciences, Istanbul Medipol University</institution></institution-wrap><addr-line><named-content content-type="city">Istanbul</named-content></addr-line><country>Turkey</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/037jwzz50</institution-id><institution>Cancer Research Center, Institute for Health Sciences and Technologies (SABITA), Istanbul Medipol University</institution></institution-wrap><addr-line><named-content content-type="city">Istanbul</named-content></addr-line><country>Turkey</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/049asqa32</institution-id><institution>Faculty of Engineering and Natural Sciences, Sabanci University</institution></institution-wrap><addr-line><named-content content-type="city">Istanbul</named-content></addr-line><country>Turkey</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/037jwzz50</institution-id><institution>Department of Medical Biology, International School of Medicine, Istanbul Medipol University</institution></institution-wrap><addr-line><named-content content-type="city">Istanbul</named-content></addr-line><country>Turkey</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/037jwzz50</institution-id><institution>Department of Computer Engineering, School of Engineering and Natural Sciences, Istanbul Medipol University</institution></institution-wrap><addr-line><named-content content-type="city">Istanbul</named-content></addr-line><country>Turkey</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/037jwzz50</institution-id><institution>Regenerative and Restorative Medicine Research Center (REMER), Institute for Health Sciences and Technologies (SABITA), Istanbul Medipol University</institution></institution-wrap><addr-line><named-content content-type="city">Istanbul</named-content></addr-line><country>Turkey</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Cui</surname><given-names>Qiang</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05qwgg493</institution-id><institution>Boston University</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Cooper</surname><given-names>Jonathan A</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Fred Hutchinson Cancer Research Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn><fn fn-type="present-address" id="pa1"><label>‡</label><p>Molecular Simulations and Design Group,Max Planck Institute for Dynamicsof Complex Technical Systems, Magdeburg, Germany</p></fn><fn fn-type="present-address" id="pa2"><label>§</label><p>Department of Applied Physics,Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>02</day><month>12</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e79747</elocation-id><history><date date-type="received" iso-8601-date="2022-04-25"><day>25</day><month>04</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-11-30"><day>30</day><month>11</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-04-24"><day>24</day><month>04</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.04.24.489309"/></event></pub-history><permissions><copyright-statement>© 2022, Ilter, Kasmer et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Ilter, Kasmer et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-79747-v3.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-79747-figures-v3.pdf"/><abstract><p>Undruggability of RAS proteins has necessitated alternative strategies for the development of effective inhibitors. In this respect, phosphorylation has recently come into prominence as this reversible post-translational modification attenuates sensitivity of RAS towards RAF. As such, in this study, we set out to unveil the impact of phosphorylation on dynamics of HRAS<sup>WT</sup> and aim to invoke similar behavior in HRAS<sup>G12D</sup> mutant by means of small therapeutic molecules. To this end, we performed molecular dynamics (MD) simulations using phosphorylated HRAS and showed that phosphorylation of Y32 distorted Switch I, hence the RAS/RAF interface. Consequently, we targeted Switch I in HRAS<sup>G12D</sup> by means of approved therapeutic molecules and showed that the ligands enabled detachment of Switch I from the nucleotide-binding pocket. Moreover, we demonstrated that displacement of Switch I from the nucleotide-binding pocket was energetically more favorable in the presence of the ligand. Importantly, we verified computational findings in vitro where HRAS<sup>G12D</sup>/RAF interaction was prevented by the ligand in HEK293T cells that expressed HRAS<sup>G12D</sup> mutant protein. Therefore, these findings suggest that targeting Switch I, hence making Y32 accessible might open up new avenues in future drug discovery strategies that target mutant RAS proteins.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>hek-293t -hras-wt</kwd><kwd>eukaryotic expression plasmid</kwd><kwd>hek-293t -hras-g12d</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Other</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Health Institute of Turkey</institution></institution-wrap></funding-source><award-id>3561/2019-TA-02</award-id><principal-award-recipient><name><surname>Ilter</surname><given-names>Metehan</given-names></name><name><surname>Kasmer</surname><given-names>Ramazan</given-names></name><name><surname>Topcu</surname><given-names>Ozan</given-names></name><name><surname>Karakas</surname><given-names>Nihal</given-names></name><name><surname>Sensoy</surname><given-names>Ozge</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>The Scientific and Technological Research Council of Turkey</institution></institution-wrap></funding-source><award-id>116F229</award-id><principal-award-recipient><name><surname>Jalalypour</surname><given-names>Farzaneh</given-names></name><name><surname>Atilgan</surname><given-names>Canan</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The impact of phosphorylation on the dynamics of RAS is considered to find allosteric binding sites on the flat surface of the protein, to which small molecules could bind and perturb the RAS-RAF interaction interface.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The RAS gene family translates into four proteins, namely HRAS, NRAS, KRAS4A, and KRAS4B, that control mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K), and Ras-like (RAL) pathways (<xref ref-type="bibr" rid="bib5">Barbacid, 1987</xref>; <xref ref-type="bibr" rid="bib62">Malumbres and Barbacid, 2003</xref>; <xref ref-type="bibr" rid="bib60">Lu et al., 2016a</xref>; <xref ref-type="bibr" rid="bib46">Khan et al., 2019</xref>; <xref ref-type="bibr" rid="bib23">Duffy and Crown, 2021</xref>; <xref ref-type="bibr" rid="bib86">Simanshu et al., 2017</xref>; <xref ref-type="bibr" rid="bib26">Ferro and Trabalzini, 2010</xref>; <xref ref-type="bibr" rid="bib20">De Luca et al., 2012</xref>; <xref ref-type="bibr" rid="bib109">Young et al., 2013</xref>; <xref ref-type="bibr" rid="bib50">Knight and Irving, 2014</xref>). These small G proteins act as a binary switch as the activation of the protein is modulated by two types of nucleotides, namely, guanosine-triphosphate (GTP) and guanosine-diphosphate (GDP). The exchange of GDP for GTP is maintained by guanine exchange factors (GEFs) which, in turn, activates the RAS protein (<xref ref-type="bibr" rid="bib21">Downward, 1990</xref>; <xref ref-type="bibr" rid="bib30">Grand and Owen, 1991</xref>; <xref ref-type="bibr" rid="bib8">Bourne et al., 1991</xref>; <xref ref-type="bibr" rid="bib106">Wittinghofer and Pai, 1991</xref>; <xref ref-type="bibr" rid="bib59">Lowy et al., 1991</xref>; <xref ref-type="bibr" rid="bib108">Wittinghofer and Vetter, 2011</xref>; <xref ref-type="bibr" rid="bib92">Takai et al., 2001</xref>; <xref ref-type="bibr" rid="bib53">Lamontanara et al., 2014</xref>; <xref ref-type="bibr" rid="bib100">Vetter and Wittinghofer, 2001</xref>; <xref ref-type="bibr" rid="bib60">Lu et al., 2016a</xref>). Consequently, activated RAS proteins can interact with their downstream effectors, thus initiating cellular signaling pathways (<xref ref-type="bibr" rid="bib100">Vetter and Wittinghofer, 2001</xref>; <xref ref-type="bibr" rid="bib17">Cherfils and Zeghouf, 2013</xref>; <xref ref-type="bibr" rid="bib28">Geyer and Wittinghofer, 1997</xref>; <xref ref-type="bibr" rid="bib60">Lu et al., 2016a</xref>). Unlike GEFs, GTPase-activating-proteins (GAPs) accelerate the intrinsic GTPase activity of RAS, which provides a control mechanism for precise termination of respective signaling pathways (<xref ref-type="bibr" rid="bib107">Wittinghofer et al., 1997</xref>; <xref ref-type="bibr" rid="bib60">Lu et al., 2016a</xref>).</p><p>RAS proteins are made up of two domains, namely, G domain (residues 1–172) and hypervariable region (173–188 or –189) (<xref ref-type="bibr" rid="bib72">O’Bryan, 2019</xref>; <xref ref-type="bibr" rid="bib47">Khan et al., 2020</xref>, <xref ref-type="fig" rid="fig1">Figure 1A</xref>). The G domain consists of effector (residues 1–86) and allosteric lobes (residues 87–172). The former, which is the invariant region, harbors the P-loop (residues 10–17), Switch I (30-38), and Switch II (59-76) regions, the last two of which adopt different conformational states depending on the type of the nucleotide (<xref ref-type="bibr" rid="bib102">Wang et al., 2021</xref>). In particular, Switch I/II can be found in either open or closed conformation, both of which are described depending on the position of the domain with respect to the nucleotide-binding pocket. In the open conformation, Switch I/II is far from the nucleotide-binding pocket, whereas it is closer in the closed conformation. Importantly, the former prevents effector binding while the latter favors it. Moreover, it has been also shown that Switch II becomes less stable upon effector binding, which presumably allows RAS to cycle between catalytically incompetent and competent states in a timely manner that is important for maintaining the cell homeostasis (<xref ref-type="bibr" rid="bib43">Johnson and Mattos, 2013</xref>; <xref ref-type="bibr" rid="bib47">Khan et al., 2020</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>RAS phosphorylation/dephosphorylation cycle.</title><p>(<bold>a</bold>) Important residues/regions that play pivotal role in RAS function are shown. (<bold>b</bold>) A schematic that illustrates the impact of tyrosyl phosphorylation on the GTPase cycle of HRAS. The tyrosyl phosphorylation at the 32<sup>nd</sup> position, which is mediated by Src kinase, causes impairment of RAF binding, thus terminating RAF/MEK/ERK signaling pathway as long as the phosphoryl group of Y32 is not detached by SHP2 <xref ref-type="bibr" rid="bib11">Bunda et al., 2014</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79747-fig1-v3.tif"/></fig><p>Since RAS proteins are involved in signaling pathways, which are responsible for cell growth, differentiation, and proliferation, mutations, which are frequently found at the 12<sup>th</sup>, 13<sup>th</sup>, and 61<sup>st</sup> residues (<xref ref-type="bibr" rid="bib79">Prior et al., 2020</xref>; <xref ref-type="bibr" rid="bib78">Prior et al., 2012</xref>, cause several cancer types <xref ref-type="bibr" rid="bib35">Holderfield et al., 2014</xref>; <xref ref-type="bibr" rid="bib24">Eser et al., 2014</xref>; <xref ref-type="bibr" rid="bib78">Prior et al., 2012</xref>; <xref ref-type="bibr" rid="bib89">Stephen et al., 2014</xref>; <xref ref-type="bibr" rid="bib65">McCormick, 2015a</xref>; <xref ref-type="bibr" rid="bib66">McCormick, 2015b</xref>; <xref ref-type="bibr" rid="bib52">Krens et al., 2010</xref>; <xref ref-type="bibr" rid="bib60">Lu et al., 2016a</xref> as a result of attenuated GTP hydrolysis and increased nucleotide exchange rate <xref ref-type="bibr" rid="bib101">Vigil et al., 2010</xref>). For instance, HRAS<sup>G12D</sup> was shown to be the dominant mutant in ductal carcinoma (<xref ref-type="bibr" rid="bib71">Myers et al., 2016</xref>) caused resistance to erlotinib, which is used as an epidermal growth factor receptor tyrosine kinase inhibitor (<xref ref-type="bibr" rid="bib32">Hah et al., 2014</xref>), in head and neck squamous carcinoma. As such, RAS proteins have been standing as hot targets in drug discovery studies which are focused on the development of therapeutics against cancer.</p><p>In spite of extensive efforts that have been made to develop RAS inhibitors, no molecules have yet been approved for clinical use (<xref ref-type="bibr" rid="bib13">Canon et al., 2019</xref>; <xref ref-type="bibr" rid="bib23">Duffy and Crown, 2021</xref>). In these studies, the mutant RAS was targeted directly or in combination with other proteins including SOS, tyrosine kinase, SHP2, and RAF. Also, except KRAS<sup>G12C</sup> mutant, the GTP-bound state of mutants has been targeted as they either lose their intrinsic or GAP-mediated GTPase activity. However, the intrinsic GTPase activity of KRAS<sup>G12C</sup> is relatively higher than the other mutants which enables targeting in its GDP-bound state (<xref ref-type="bibr" rid="bib69">Moore et al., 2020</xref>).</p><p>The undruggability of RAS proteins arises from lack of deep binding pockets on the surface of the protein and also picomolar affinity of the endogenous ligands which hinders development of competitive inhibitors (<xref ref-type="bibr" rid="bib31">Gysin et al., 2011</xref>; <xref ref-type="bibr" rid="bib55">Ledford, 2015</xref>; <xref ref-type="bibr" rid="bib18">Cox et al., 2014</xref>; <xref ref-type="bibr" rid="bib68">Milroy and Ottmann, 2014</xref>). Therefore, much attention has been focused on the discovery of allosteric sites that can regulate the function of the protein (<xref ref-type="bibr" rid="bib10">Buhrman et al., 2010</xref>; <xref ref-type="bibr" rid="bib75">Ostrem et al., 2013</xref>; <xref ref-type="bibr" rid="bib27">Fetics et al., 2015</xref>; <xref ref-type="bibr" rid="bib44">Johnson et al., 2017</xref>; <xref ref-type="bibr" rid="bib64">McCarthy et al., 2019</xref>; <xref ref-type="bibr" rid="bib48">Khan et al., 2022</xref>).</p><p>Importantly, it is well-established that the function of the protein is modulated by post-translational modifications. In particular, phosphorylation/dephosphorylation can be given as an example, which is controlled by Src-kinase and Src homology region 2 domain-containing phosphatase-2 (SHP2), respectively (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). It has been shown that phosphorylation of the tyrosine at the 32<sup>nd</sup> position by Src-kinase attenuated RAF binding to HRAS and NRAS while elevating intrinsic GTPase activity of the proteins (<xref ref-type="bibr" rid="bib11">Bunda et al., 2014</xref>, <xref ref-type="fig" rid="fig1">Figure 1B</xref>). Furthermore, recently, Kano et al. have implied that Src-kinase phosphorylated tyrosine residues at the 32<sup>nd</sup> and 64<sup>th</sup> positions of KRAS4B isoform changed conformation of Switch I and II. Consequently, this led to a decrease in intrinsic GTPase activity, thus maintaining KRAS4B in the GTP-bound state. Interestingly, phosphorylated and GTP-bound KRAS4B was shown not to bind RAF, thus leaving the protein in the dark state (<xref ref-type="bibr" rid="bib45">Kano et al., 2019</xref>). In the same study, it was also shown that if phosphoryl groups were removed by SHP2, then GTP-bound KRAS4B could interact with RAF and initiate signaling pathways through MAPK (<xref ref-type="bibr" rid="bib45">Kano et al., 2019</xref>). Notably, it was shown that deletion or inhibition of SHP2 could slow down tumor progression, but remaining insufficient for tumor regression (<xref ref-type="bibr" rid="bib82">Ruess et al., 2018</xref>). Collectively, these findings suggest that mimicking dynamics invoked by phosphorylation might provide an alternative strategy for inhibiting mutant RAS/RAF interaction.</p><p>In this study, we set out to investigate the impact of phosphorylation on the structure and dynamics of HRAS<sup>WT</sup> by performing atomistic MD simulations. Comparison of the trajectory pertaining to the phosphorylated RAS with trajectories of GTP-bound HRAS<sup>WT</sup> and HRAS<sup>G12D</sup> showed that phosphorylation of Y32 increased the flexibility of RAF-RBD interface compared to the mutant and pushed Switch I, in particular Y32, out of the nucleotide-binding pocket. Considering the fact that, exposed Y32 precluded RAF binding, we searched for molecules that could evoke similar rearrangements in HRAS<sup>G12D</sup>. To this end, we carried out virtual screening by using therapeutically-approved molecules deposited in DrugBank (<xref ref-type="bibr" rid="bib105">Wishart et al., 2018</xref>; <xref ref-type="bibr" rid="bib54">Law et al., 2014</xref>; <xref ref-type="bibr" rid="bib51">Knox et al., 2011</xref>; <xref ref-type="bibr" rid="bib104">Wishart et al., 2008</xref>; <xref ref-type="bibr" rid="bib103">Wishart et al., 2006</xref>, BindingDB <xref ref-type="bibr" rid="bib29">Gilson et al., 2016</xref>; <xref ref-type="bibr" rid="bib57">Liu et al., 2007</xref>; <xref ref-type="bibr" rid="bib15">Chen et al., 2001b</xref>; <xref ref-type="bibr" rid="bib14">Chen et al., 2001a</xref>; <xref ref-type="bibr" rid="bib16">Chen et al., 2002</xref>, DrugCentral <xref ref-type="bibr" rid="bib96">Ursu et al., 2019</xref>; <xref ref-type="bibr" rid="bib95">Ursu et al., 2017</xref>, and NCGC <xref ref-type="bibr" rid="bib36">Huang et al., 2011</xref>). The impact of ligands on the structure and dynamics of HRAS<sup>G12D</sup> mutant was examined using molecular dynamics simulations. We showed that cerubidine, tranilast, nilotinib, and epirubicin could induce similar dynamics and structural changes which were seen in the phosphorylated RAS protein. Moreover, we also calculated the energy required for pushing Switch I out of the nucleotide-binding pocket in the absence/presence of one of the successful ligands, namely cerubidine, using perturb-scan-pull (PSP) method <xref ref-type="bibr" rid="bib40">Jalalypour et al., 2020</xref> and showed that less energy was required for displacement of Switch I in the presence of the ligand. Importantly, we also tested the activity of cerubidine in preventing RAS/RAF interaction using immunoprecipitation assays and verified computational findings. Therefore, these results suggest that Y32 detachment from the nucleotide-binding pocket might be used as an alternative strategy for targeting mutant RAS proteins.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Phosphorylation impacts the flexibility of Y32 and RAF-RBD/RAS interface residues</title><p>The comparison of RMSF profiles showed remarkable differences in the fluctuation patterns of certain residues/domains among wild-type, phosphorylated, and mutant protein. We showed that phosphorylation increased the flexibility of Y32 as a result of repulsion between negatively charged phosphate and GTP and also increased the flexibility of the residues that are involved in the RAF-RBD interaction interface compared to the mutant as shown in <xref ref-type="table" rid="table1">Table 1</xref>. Since RAF-RBD plays a major role in formation of high-affinity RAS-RAF complex, increased flexibility presumably precludes RAF binding. On the other hand, phosphorylation did not impact the RAF-CRD interface, which has been shown to play an important role in anchoring RAF to the membrane (<xref ref-type="bibr" rid="bib94">Travers et al., 2018</xref>) as revealed by NMR and mutagenesis studies (<xref ref-type="bibr" rid="bib22">Drugan et al., 1996</xref>). It is important to note that the difference seen in the flexibility of Y32 and RAF-RBD interface residues between HRAS<sup>pY32</sup> and HRAS<sup>G12D</sup> could not be observed for G60 and Q61, although the two residues could reach relatively higher RMSF values in the phosphorylated RAS (see the standard errors in <xref ref-type="table" rid="table1">Table 1</xref>). This, in turn, which might cause perturbation of the interface formed with RAF-CRD and modulate GAP-mediated GTPase activity of RAS, respectively.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>The backbone RMSF values of key regions/residues pertaining to HRAS<sup>WT</sup>, HRAS<sup>pY32</sup>, and HRAS<sup>G12D</sup>.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Residue/Region-RMSF (Å)</th><th align="left" valign="bottom">HRAS<sup>WT</sup></th><th align="left" valign="bottom">HRAS<sup>pY32</sup></th><th align="left" valign="bottom">HRAS<sup>G12D</sup></th></tr></thead><tbody><tr><td align="left" valign="bottom">Y32</td><td align="char" char="." valign="bottom">1.6 ± 0.2</td><td align="char" char="." valign="bottom">1.5± 0.2</td><td align="char" char="." valign="bottom">0.9± 0.1</td></tr><tr><td align="left" valign="bottom">RAF-RBD interface residues</td><td align="char" char="." valign="bottom">1.2± 0.2</td><td align="char" char="." valign="bottom">1.3± 0.2</td><td align="char" char="." valign="bottom">0.8± 0.1</td></tr><tr><td align="left" valign="bottom">RAF-CRD interface residues</td><td align="char" char="." valign="bottom">0.8± 0.1</td><td align="char" char="." valign="bottom">0.9± 0.2</td><td align="char" char="." valign="bottom">0.7± 0.03</td></tr><tr><td align="left" valign="bottom">G60</td><td align="char" char="." valign="bottom">1.0± 0.3</td><td align="char" char="." valign="bottom">1.4± 0.5</td><td align="char" char="." valign="bottom">1.1± 0.2</td></tr><tr><td align="left" valign="bottom">Q61</td><td align="char" char="." valign="bottom">1.2± 0.4</td><td align="char" char="." valign="bottom">1.6± 0.4</td><td align="char" char="." valign="bottom">1.5± 0.3</td></tr></tbody></table></table-wrap></sec><sec id="s2-2"><title>Phosphorylation pushes Switch I and Y32 out of the nucleotide-binding pocket of RAS</title><p>As shown in <xref ref-type="table" rid="table1">Table 1</xref>, the flexibility of residues, which interact with RAF-CRD domain, increased upon phosphorylation compared to HRAS<sup>G12D</sup>. Since these residues surround the Switch I domain, we sought to investigate whether the opening of the nucleotide-binding pocket was impacted by measuring the distance between Cα atoms of the G/D12 and P34 residues throughout the trajectories. We showed that phosphorylation pushed Switch I out of the binding pocket as the distance between G12 and P34 residues increased compared to the mutant protein (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A-C</xref>). Consequently, this makes the nucleotide-binding pocket more accessible to waters, as evident from the number of waters measured within 5 Å distance of GTP: 93.60±0.20, 100.30±0.20, and 72.68±0.17 for HRAS <sup>WT</sup>, HRAS<sup>pY32</sup>, and HRAS<sup>G12D</sup>,respectively. Considering rearrangements occurring around the nucleotide-binding pocket and that GAP binding involves interaction with both Switch I and II, it can be said that phosphorylation triggers rearrangement around the pocket of RAS that prepares it for binding to GAP, thus, modulating the GTPase activity of the protein. Indeed, it was shown that GTPase activity of RAS increased upon phosphorylation (<xref ref-type="bibr" rid="bib11">Bunda et al., 2014</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Probability distance distributions pertaining to nucleotide binding pocket and respective schematic representation of the residues used for the calculations.</title><p>(<bold>a</bold>) The normalized probability density distribution of the distance measured between the Cα atom of 12<sup>th</sup> 34<sup>th</sup> residues. The standard error (SE) of the measurements for HRAS<sup>pY32</sup>, HRAS<sup>WT</sup>, and HRAS<sup>G12D</sup> are measured as 0.01, 0.004, and 0.01 Å, respectively. (<bold>b</bold>) The normalized probability distribution of the distance between the side-chain oxygen atom of Y32 and Pγ of GTP. The SE of the measurements for HRAS<sup>pY32</sup>, HRAS<sup>WT</sup>, and HRAS<sup>G12D</sup> are calculated as 0.02, 0.02, and 0.003 Å, respectively. (<bold>c</bold>) Cα atoms of 12<sup>th</sup> and 34<sup>th</sup> residues are shown on the crystal structure of HRAS<sup>WT</sup> (PDB ID: 5P21) in vdW representation and colored with ocher and purple, respectively, whereas GTP is shown in the licorice and colored with red. (<bold>d</bold>) The orientational dynamics of Y32 in the HRAS<sup>pY32</sup> trajectory. (<bold>e</bold>) The H-bond formed between side-chain of Y32 and Pγ of GTP in HRAS<sup>G12D</sup> is shown in purple.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79747-fig2-v3.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>The timeline interatomic distances between Cα atoms of G/D12 and D34 throughout (<bold>a</bold>) HRAS<sup>WT</sup>, (<bold>b</bold>) HRAS<sup>G12D</sup>, and (<bold>c</bold>) HRAS<sup>pY32</sup> trajectories.</title><p>The timeline interatomic distances between OH atom of Y32 and Pγ atom of GTP throughout (<bold>d</bold>) HRAS<sup>WT</sup>, (<bold>e</bold>) HRAS<sup>G12D</sup>, and (<bold>f</bold>) HRAS<sup>pY32</sup> trajectories.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79747-fig2-figsupp1-v3.tif"/></fig></fig-group><p>Having observed phosphorylation-induced modulation in the flexibility of Y32, we also examined the positioning of the residue by measuring the distance between the side-chain oxygen of Y32 and Pγ atom of GTP (see <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D,E and F</xref>). We showed that Y32 formed a hydrogen bond with the Pγ atom of GTP in both HRAS<sup>WT</sup> and HRAS<sup>G12D</sup> which stabilized the residue in the vicinity of the nucleotide-binding pocket (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). However, the hydrogen bond was not formed in HRAS<sup>pY32</sup>, and Y32 was positioned far from the pocket, thus making it exposed to the environment, as evidenced by relatively longer distances measured (<xref ref-type="fig" rid="fig2">Figure 2B and D</xref>). In addition to the position, we also explored orientational preference of Y32 with respect to the nucleotide-binding pocket by measuring dihedral angles pertaining to backbone and side-chains of Y32, namely <inline-formula><mml:math id="inf1"><mml:mi>ϕ</mml:mi></mml:math></inline-formula>/<inline-formula><mml:math id="inf2"><mml:mi>ψ</mml:mi></mml:math></inline-formula> and <inline-formula><mml:math id="inf3"><mml:mi>χ</mml:mi></mml:math></inline-formula><sub>1</sub>/<inline-formula><mml:math id="inf4"><mml:mi>χ</mml:mi></mml:math></inline-formula><sub>2</sub> angles. There was no remarkable difference in backbone dihedrals and <inline-formula><mml:math id="inf5"><mml:mi>χ</mml:mi></mml:math></inline-formula><sub>1</sub>, whereas <inline-formula><mml:math id="inf6"><mml:mi>χ</mml:mi></mml:math></inline-formula><sub>2</sub> angle distribution was different among the systems studied. Specifically, Y32 displayed two peaks at –100 to –90° and 80–90° in the phosphorylated RAS, whereas it adopted 60–70° in the mutant and wild-type HRAS (<xref ref-type="fig" rid="fig3">Figure 3A</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). It is important to point that Y32 adopted 80° in the crystal structure of allosteric inhibitor-bound KRAS4B<sup>G12D</sup> (PDB ID:6WGN) <xref ref-type="bibr" rid="bib111">Zhang et al., 2020</xref>, where the residue was exposed and far from the nucleotide-binding pocket as the distance measured between the side-chain of Y32 and Pγ atom of GTP was 16 Å.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>The normalized probability density distribution plots pertaining to chi2 angle of residue Y32 along with respective snapshot.</title><p>(<bold>a</bold>) The normalized probability density distribution of the measured χ<sub>2</sub> angles of HRAS<sup>WT</sup>, HRAS<sup>G12D</sup>, and HRAS<sup>pY32</sup>. The SE of χ<sub>2</sub> pertaining to the phosphorylated, wild-type, and mutant systems are 0.44, 0.35, and 0.09, respectively. (<bold>b</bold>) A representative exposed state of Y32 obtained from the trajectory of the phosphorylated system.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79747-fig3-v3.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>The timeline measured χ<sub>2</sub> angles of Y32 throughout (<bold>a</bold>) HRAS<sup>WT</sup>, (<bold>b</bold>) HRAS<sup>G12D</sup>, and (<bold>c</bold>) HRAS<sup>pY32</sup> trajectories.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79747-fig3-figsupp1-v3.tif"/></fig></fig-group><p>Herein, it is important to mention that exposed conformation of Y32 was not observed in the trajectories pertaining to RAF-RBD-bound HRAS<sup>WT</sup> as shown in our earlier study (<xref ref-type="bibr" rid="bib39">Ilter and Sensoy, 2019</xref>). Therefore, this finding suggests that exposure of Y32 might occlude the interaction interface formed between RAS and RAF-RBD.</p></sec><sec id="s2-3"><title>Global dynamics reveals a possible binding site near the nucleotide-binding pocket in HRAS<sup>G12D</sup></title><p>Besides local analysis, the collective dynamic properties of the systems were also explored by calculating the principal components of their global motions. To do so, trajectories of HRAS<sup>WT</sup>, HRAS<sup>G12D</sup>, and HRAS<sup>pY32</sup> were projected along their first five eigenvectors, which reflect <italic>ca</italic>. 50% of the overall dynamics <xref ref-type="bibr" rid="bib77">Petrone and Pande, 2006</xref> (see <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>), and compared to each other to investigate global conformational rearrangements induced by phosphorylation and mutation. Consequently, it was shown that the dynamics of Switch I domain, in particular RAF-RBD interaction interface, could be altered in the mutant, albeit to a lesser extent, compared to both HRAS<sup>WT</sup>, HRAS<sup>pY32</sup>. It is also important to mention that the contribution of Y32 to the first five eigenvectors was higher in HRAS<sup>pY32</sup> (3.14 Å) than in the mutant protein (2.87 Å) as seen in the RMSF values.</p><p>ON the other hand, the contribution of Switch II, which harbors both G60 and Q61, to the overall dynamics was higher in HRAS<sup>WT</sup> and HRAS<sup>pY32</sup> than the mutant protein (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Q61 was positioned closer to the nucleotide-binding pocket in the mutant HRAS than in phosphorylated HRAS whereas G60 could sample longer distances than that was sampled by both HRAS<sup>pY32</sup> and HRAS<sup>WT</sup> at their maximum probability (<xref ref-type="fig" rid="fig4">Figure 4C and D</xref> and <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>PCA analysis and Distance Probability Distributions pertaining to G60/Q61 and the nucleotide.</title><p>(<bold>a</bold>) Fluctuation of Cα atoms pertaining to HRAS<sup>WT</sup>, HRAS<sup>G12D</sup>, and HRAS<sup>pY32</sup> along the first five eigenvectors. The RAF-CRD &amp; -RBD interaction interfaces, as well as Switch II, are shaded in the green, pink, and black rectangles, respectively. The eigen RMSF of Y32 pertaining to the phosphorylation system is pointed out by a dark violate bead. (<bold>b</bold>) The projected trajectories of the systems studied along with the first principal component, where the thickness of the ribbons are correlated the contribution of domain to the collective dynamics. The probability density distribution of the distance between (<bold>c</bold>) the backbone amide of G60 and Pγ of GTP is shown, and (<bold>d</bold>) the side-chain oxygen of Q61 and Pγ of GTP is shown. The SE of the distance between G60 and GTP pertaining to the phosphorylated, wild-type, and mutant systems are 0.01, 0.01, and 0.004 Å, respectively. The SE of the distance between Q61 and GTP pertaining to the phosphorylated, wild-type, and mutat systems are 0.02, 0.01, and 0.01, respectively.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79747-fig4-v3.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>The cumulative contribution of the principal components pertaining to the (<bold>a</bold>) phosphorylated, (<bold>b</bold>) wild-type, and (<bold>c</bold>) G12D mutant systems to the overall dynamics.</title><p>The contribution of the first five principal components are denoted by a cross symbol on the plots.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79747-fig4-figsupp1-v3.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>The timeline of the measured distances between HN of G60 and Pγ of GTP for (<bold>a</bold>) wild-type, (<bold>b</bold>) mutant, and (<bold>c</bold>) phosphorylated systems.</title><p>The timeline of the measured distances between Oε1 of Q61 and Pγ of GTP for (d) wild-type, (e) mutant, and (f) phosphorylated systems.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79747-fig4-figsupp2-v3.tif"/></fig></fig-group><p>Having observed flexibility at the RAF-RBD interface in the mutant, we set out to investigate if the site can be considered as a possible binding pocket that can accommodate small molecules to modulate the dynamics of Switch I. To do so, we clustered the trajectory of the mutant HRAS by considering probability density distributions of distances between the (i) side-chain oxygen of T35 and Pγ of GTP (ii) backbone amide of G60 and Pγ of GTP, which represent different conformational states of the nucleotide-binding pocket, according to the structural studies (<xref ref-type="bibr" rid="bib61">Lu et al., 2016b</xref>; <xref ref-type="bibr" rid="bib85">Shima et al., 2010</xref>; <xref ref-type="bibr" rid="bib2">Araki et al., 2011</xref>). There were three states described for T35, labelled as state 1, 2, and 3, each of which sampled distances in the range of 3.0–5.0 Å, 6.0–9.0 Å, and 12.0–16.0 Å, respectively (<xref ref-type="fig" rid="fig5">Figure 5A</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Similarly, G60 could also adopt three states, namely state 1, 2, and 3, which corresponds to distance range between 5.0–7.0 Å, 2.0–4.0 Å, and 8.0–9.0 Å, respectively (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). In light of clustered conformations, the most probable conformation that adopts values pertaining to State 1 in each atom-pair distances was picked up from the trajectory of HRAS<sup>G12D</sup>. The possible binding pockets on the surface of mutant HRAS were identified and evaluated by comparing SiteMap scores. Eventually, the pocket, which had relatively higher SiteScore, enclosure and lower exposure, was selected to be used further (<xref ref-type="table" rid="table2">Table 2</xref>). The binding pocket, which was identified on the selected conformation, was next to Switch I. Considering the fact that this domain (i) includes residues that mediate RAF binding, (ii) acts as a regulator for intrinsic GTPase activity, and (iii) dominates the collective dynamics of the mutant protein, the region was used as the target binding pocket in the subsequent steps of the study.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Probability distribution plot pertaining to distance measured between T35 (Ogamma)-GTP(Pgamma) and G60 (HN)-GTP (Pgamma) for the most populated conformational state of mutant H-RAS.</title><p>The normalized probability density distribution of the measured distance between the side-chain oxygen atom of T35 and Pγ of GTP, and the backbone amide of G60 and Pγ of GTP in the mutant system, where the sampling range for calculating the frequency of each interval was adjusted as 1 Å. The SE of the distance between T35 and GTP is calculated as 0.001 Å, whereas that of the distance between G60 and GTP is 0.004 Å.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79747-fig5-v3.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>The (<bold>a</bold>) timeline and (<bold>b</bold>) histogram of the measured distance between O1 of T35 and Pγ of GTP for the mutant system.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79747-fig5-figsupp1-v3.tif"/></fig></fig-group><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>The SiteMap scores of possible pockets found on the surface of the most probable conformation of HRAS<sup>G12D</sup>.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">SiteScore</th><th align="left" valign="bottom">Size</th><th align="left" valign="bottom">DScore</th><th align="left" valign="bottom">Volume</th><th align="left" valign="bottom">Exposure</th><th align="left" valign="bottom">Enclosure</th><th align="left" valign="bottom">Contact</th><th align="left" valign="bottom">Phobic</th><th align="left" valign="bottom">Philic</th><th align="left" valign="bottom">Balance</th><th align="left" valign="bottom">Don/acc</th></tr></thead><tbody><tr><td align="char" char="." valign="bottom">1.028</td><td align="char" char="." valign="bottom">194</td><td align="char" char="." valign="bottom">0.919</td><td align="char" char="." valign="bottom">466.140</td><td align="char" char="." valign="bottom">0.478</td><td align="char" char="." valign="bottom">0.740</td><td align="char" char="." valign="bottom">1.010</td><td align="char" char="." valign="bottom">0.259</td><td align="char" char="." valign="bottom">1.425</td><td align="char" char="." valign="bottom">0.182</td><td align="char" char="." valign="bottom">0.932</td></tr><tr><td align="char" char="." valign="bottom">0.701</td><td align="char" char="." valign="bottom">25</td><td align="char" char="." valign="bottom">0.668</td><td align="char" char="." valign="bottom">81.290</td><td align="char" char="." valign="bottom">0.632</td><td align="char" char="." valign="bottom">0.691</td><td align="char" char="." valign="bottom">1.059</td><td align="char" char="." valign="bottom">1.474</td><td align="char" char="." valign="bottom">0.664</td><td align="char" char="." valign="bottom">2.219</td><td align="char" char="." valign="bottom">0.915</td></tr><tr><td align="char" char="." valign="bottom">0.656</td><td align="char" char="." valign="bottom">22</td><td align="char" char="." valign="bottom">0.629</td><td align="char" char="." valign="bottom">101.870</td><td align="char" char="." valign="bottom">0.776</td><td align="char" char="." valign="bottom">0.638</td><td align="char" char="." valign="bottom">0.842</td><td align="char" char="." valign="bottom">0.959</td><td align="char" char="." valign="bottom">0.596</td><td align="char" char="." valign="bottom">1.609</td><td align="char" char="." valign="bottom">12.216</td></tr></tbody></table></table-wrap></sec><sec id="s2-4"><title>Small therapeutic molecules distort the RAF binding interface and pushes Y32 out of the pocket</title><p>The pharmacophore groups of the binding site identified on the surface of HRAS<sup>G12D</sup> were modeled with respect to both geometrical and chemical properties of residues 29–34. DrugBank (<xref ref-type="bibr" rid="bib105">Wishart et al., 2018</xref>; <xref ref-type="bibr" rid="bib54">Law et al., 2014</xref>; <xref ref-type="bibr" rid="bib51">Knox et al., 2011</xref>; <xref ref-type="bibr" rid="bib104">Wishart et al., 2008</xref>; <xref ref-type="bibr" rid="bib103">Wishart et al., 2006</xref>, DrugCentral <xref ref-type="bibr" rid="bib96">Ursu et al., 2019</xref>; <xref ref-type="bibr" rid="bib95">Ursu et al., 2017</xref>, BindingDB <xref ref-type="bibr" rid="bib29">Gilson et al., 2016</xref>; <xref ref-type="bibr" rid="bib57">Liu et al., 2007</xref>; <xref ref-type="bibr" rid="bib15">Chen et al., 2001b</xref>; <xref ref-type="bibr" rid="bib14">Chen et al., 2001a</xref>; <xref ref-type="bibr" rid="bib16">Chen et al., 2002</xref>, and NCGC <xref ref-type="bibr" rid="bib36">Huang et al., 2011</xref>) databases were searched for molecules that could contain at least three features of the modeled pharmacophores and have molecular weight lower than 550 kDa. A total of 4292 molecules was retrieved from the databases (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Then, these molecules were docked to the identified binding pocket on the surface of HRAS<sup>G12D</sup> and ligands were evaluated with respect to their spatial organization around the nucleotide-binding pocket and GScores, which is a term that is used to score binding poses in Schrodinger. Considering the close interaction observed between Y32 and GTP in HRAS<sup>G12D</sup>, we prioritized the ligands, which disrupted interaction between the nucleotide and Y32. The impact of four ligands satisfying this criterion, namely cerubidine, tranilast, nilotinib, and epirubicin, (<xref ref-type="fig" rid="fig6">Figure 6B-E</xref>) was further tested by performing MD simulations using the ligand-HRAS<sup>G12D</sup> complex (See <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref> for respective simulation times).</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Virtual screening scheme used, and candidate molecules achieved along with their chemical structures and docking energy values.</title><p>(<bold>a</bold>) A schematic that summarizes the virtual screening workflow done for the identified binding pocket on the most frequently sampled conformation of HRAS<sup>G12D</sup>. The 3D structures and corresponding GScores of (<bold>b</bold>) cerubidine, (<bold>c</bold>) epirubicin, (<bold>d</bold>) tranilast, and (<bold>e</bold>) nilotinib are shown. GTP is shown in licorice and red.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79747-fig6-v3.tif"/></fig><p>The ligand-HRAS<sup>G12D</sup> trajectories were analyzed based on the fluctuation pattern of RAF-RBD, RAF-CRD, and Y32. Moreover, the distances measured between G/D12 and P34 as well as Y32 and GTP were also compared to those of HRAS<sup>G12D</sup> and HRAS<sup>pY32</sup>. In that way, the capability of the ligands in distorting Switch I domain, widening the nucleotide-binding pocket, and displacing Y32 could be investigated. Accordingly, ligands, which could (i) increase the flexibility of RAF-RBD and -CRD interfaces, and (ii) displace Switch I and Y32 from the nucleotide-binding pocket were considered successful in terms of preventing HRAS<sup>G12D</sup>/RAF interaction. We showed that all the ligands, namely cerubidine, nilotinib, tranilast, and epirubicin, considerably increased the flexibility of the RAF-RBD interaction interface (See <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) than in HRAS<sup>G12D</sup>. Moreover, the flexibility of Y32, also significantly increased by all the ligands, except nilotinib (<xref ref-type="bibr" rid="bib11">Bunda et al., 2014</xref>; <xref ref-type="bibr" rid="bib45">Kano et al., 2019</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>).</p><p>We also examined the wideness of the nucleotide-binding pocket and the positioning of Y32 by measuring the distances between G/D12, respectively. We showed that cerubudine was more likely to trigger displacement of Switch I and Y32 away from the nucleotide-binding pocket, whereas the impact of nilotinib and epirubicin was not remarkable (See <xref ref-type="fig" rid="fig7">Figure 7A and B</xref>). This, in turn, explains accommodation of relatively higher number of waters within the nucleotide-binding pocket in cerubidine-bound HRAS<sup>G12D</sup> (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Therefore, it is tempting to suggest that cerubidine can help elevate the intrinsic GTPase activity of the mutant RAS by exposing GTP to water.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>The normalized probability density distribution plots pertaining to distances of G/D12 (Calpha)- and D34 (Calpha), Y32 (OH)-GTP (Pgamma) and chi2 angle of Y32 measured in ligand-bound mutant H-RAS trajectories.</title><p>The normalized probability density distribution of (<bold>a</bold>) the distance between Cα atoms of G/D12 and P34, (<bold>b</bold>) the distance between the side-chain oxygen atom of Y32 and Pγ of GTP, (<bold>c</bold>) χ<sub>2</sub> in HRAS<sup>G12D</sup>, HRAS<sup>pY32</sup>, and cerubidine-, tranilast-, nilotinib-, and epirubicin-bound HRAS<sup>G12D</sup>. The SE of the G/D12-D34 distance pertaining to the above-mentioned systems, in seriatim, 0.01, 0.01, 0.02, 0.02, 0.03, and 0.03 Å. The SE of the same systems for Y32-GTP distance is 0.003, 0.02, 0.02, 0.03, 0.02, 0.04 Å, respectively. The SE of χ<sub>2</sub> is 0.09, 0.44, 0.37, 0.39, 0.51, and 0.39 degree for the mutant, phosphorylated, cerubidine-, tranilast-, nilotinib, and epirubicin-bound HRAS<sup>G12D</sup> systems, respectively.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79747-fig7-v3.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>The timeline and histogram of the measured distances between Cα atoms of D12 and D34 for (<bold>a,e</bold>) cerubidine-bound, (<bold>b,f</bold>) tranilast-bound, (<bold>c,g</bold>) nilotinib-bound, and (<bold>d,h</bold>) epirubicin-bound HRAS<sup>G12D</sup> systems, respectively.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79747-fig7-figsupp1-v3.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>The timeline and histogram of the measured χ<sup>2</sup> angles pertaining to Y32 for (<bold>a</bold>) cerubidine-bound, (<bold>b</bold>) tranilast-bound, (<bold>c</bold>) nilotinib-bound, and (<bold>d</bold>) epirubicin-bound HRAS<sup>G12D</sup> systems.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79747-fig7-figsupp2-v3.tif"/></fig></fig-group><p>Also, Y32 adopted similar <inline-formula><mml:math id="inf7"><mml:mi>χ</mml:mi></mml:math></inline-formula><sub>2</sub> angle in cerubidine-bound HRAS<sup>G12D</sup> to that in the phosphorylated RAS (<xref ref-type="fig" rid="fig7">Figure 7C</xref> and <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>). Considering similarities between ligand-bound HRAS<sup>G12D</sup> and HRAS<sup>pY32</sup>, cerubidine can be thought to have relatively more potential for preventing HRAS<sup>G12D</sup>/RAF interaction. Therefore, we used cerubidine in the subsequent steps of the study to test our proof-of-concept.</p></sec><sec id="s2-5"><title>Perturb-Scan-Pull method reveals that displacement of Switch I and Y32 in HRAS<sup>G12D</sup> is favored in the presence of cerubidine</title><p>We further set out to investigate if displacement of Switch I and Y32 is energetically favorable in the presence of the cerubidine. To do so, we applied perturb-scan-pull (PSP) method (<xref ref-type="bibr" rid="bib40">Jalalypour et al., 2020</xref>), which was developed to investigate conformational transitions in proteins, on cerubidine-bound HRAS<sup>G12D</sup>. In this approach, initial and target states are described and the most possible path for transitioning between the initial and the target state is determined by calculating the overlap between the states. The maximum overlap is thought to give the optimum conformational transition path. To be consistent with the previous analyses, we used the same reaction coordinates, such as the distance between (i) Cα atoms of D12 and P34, and (ii) the backbone amide of G60 and Pγ of GTP, as the reaction coordinates, which, reflected dynamics of Switch I and II, respectively. Accordingly, we described three and two states for Switch I and II, respectively, considering the conformations obtained by clustering of HRAS<sup>G12D</sup> trajectory. Accordingly, for Switch I, if the measured distance between Cα atoms of D12 and P34 is less than 8 Å, Switch I is grouped as in the closed state. On the other hand, when the atom-pair distance is above 16 Å, Switch I grouped as in the open state. The distance between 8 and 16 Å is grouped as the partially open state of Switch I. Likewise, we also determined the state of the Switch II by measuring the distance between the backbone amide of G60 and Pγ of GTP. If the distance is above 11 Å, Switch II is grouped as in the open state, if not, in the closed state. In light of these atom-pair distances, the initial state was described as the closed state of both Switch I and II domains, since it was the most frequently sampled conformation in trajectories of the mutant HRAS. As to the target states, we described three such scenarios as shown in <xref ref-type="fig" rid="fig8">Figure 8</xref>. The target state-1 was described, as the open state of Switch I and the closed state of Switch II, whereas the target state-2 was described as the partially open state of Switch I and the open state of Switch II. The target state-3 corresponded to the open state of Switch I and II as shown in <xref ref-type="fig" rid="fig8">Figure 8</xref>.</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>A schematic that illustrates the PRS calculations made for examining the transition between the initial and target states.</title><p>The initial state represents the conformation of the closed-state of Switch I and II. The target state-1 is described as the open state of Switch I (blue) and close state of Switch II (purple). The target state-2 represents the partially open state of Switch I and open state of Switch II. The target state-3 corresponds to open state of Switch I and II.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79747-fig8-v3.tif"/></fig><p>We applied the PSP method (<xref ref-type="bibr" rid="bib40">Jalalypour et al., 2020</xref>) on the three scenarios given in <xref ref-type="fig" rid="fig8">Figure 8</xref>. The results showed that transition between the initial state and the target state-1 gave the highest overlap compared to other two states of the final state as shown in <xref ref-type="table" rid="table3">Table 3</xref>. Therefore, this finding shows that Switch I residues mainly contributed to the conformational transition of displacement of Switch I out of the nucleotide-binding pocket in HRAS<sup>G12D</sup>.</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>The results of PRS calculations for the transition between initial and target states.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Ligand</th><th align="left" valign="bottom">State</th><th align="left" valign="bottom">D12-P34 (Å)</th><th align="left" valign="bottom">G60-GTP (Å)</th><th align="left" valign="bottom">PRS selected residues</th><th align="left" valign="bottom">PRS overlap(<italic>O</italic><sup><italic>i</italic></sup>)</th></tr></thead><tbody><tr><td align="left" valign="bottom">Cerubidine<sup>a</sup></td><td align="left" valign="bottom">Initial state<sup>b</sup></td><td align="char" char="." valign="bottom">7.7 (closed)</td><td align="char" char="." valign="bottom">7.0 (closed)</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>Target state-1</bold></td><td align="char" char="." valign="bottom"><bold>26.3 (open)</bold></td><td align="char" char="." valign="bottom"><bold>11.00 (closed)</bold></td><td align="char" char="." valign="bottom"><bold>34, 35, 33, 32, 37, 36</bold></td><td align="char" char="ndash" valign="bottom"><bold>0.74–0.70</bold></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Target state-2</td><td align="left" valign="bottom">13.9 (partially open)</td><td align="char" char="." valign="bottom">15.00 (open)</td><td align="char" char="." valign="bottom">35, 34, 33, 66, 16, 65</td><td align="char" char="ndash" valign="bottom">0.58–0.50</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Target state-3</td><td align="char" char="." valign="bottom">19.5 (open)</td><td align="char" char="." valign="bottom">16.9 (open)</td><td align="char" char="." valign="bottom">34, 66, 35, 64, 16, 33</td><td align="char" char="ndash" valign="bottom">0.59–0.50</td></tr></tbody></table></table-wrap><p>We further investigated if cerubidine facilitated displacement of Switch I in terms of the energetic cost required. To this end, we performed steered molecular dynamics simulations by using ligand-free and cerubidine-bound HRAS<sup>G12D</sup> systems using the coordinates obtained by PRS method as shown in bold in <xref ref-type="table" rid="table3">Table 3</xref>. Y32 and its best direction with overlap values (<italic>O<sup>i</sup></italic>) of 0.72 were fed to SMD simulation. The initial structure was then perturbed by pulling the Cα atom of Y32 along this direction towards the target state-1. Each simulation was repeated 70 times and the potential of mean force (PMF) was calculated. We note that in the ligand-free simulations, 9 of the pullings led to diverging paths and were excluded from the analyses as they caused erroneous free energy287 estimates (see <xref ref-type="fig" rid="fig9">Figure 9B</xref>), <xref ref-type="bibr" rid="bib9">Bray et al., 2022</xref>. Conversely, in the ligand-bound SMD simulations, all simulations were on the path (see <xref ref-type="fig" rid="fig9">Figure 9B</xref>). Results displayed in <xref ref-type="fig" rid="fig9">Figure 9</xref> indicate that while the ligand-free Ras favors the open form by 3.5 kcal/mol, there is a high barrier to the opening of the cavity of ca. 30 kcal/mol. In the presence of cerubidine, the opening is achieved with a barrierless transition. This finding shows that cerubidine facilitates the lowering of the potential barrier to the opening of Switch I and exposure of Y32.</p><fig-group><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>PMF along the PSP predicted coordinate with the highest overlap for the transition scenario 1 (Switch I opening motion) as a function of distance.</title><p>PMF is calculated for the HRAS<sup>G12D</sup> system in the presence and absence of cerubidine, and each simulation was repeated 70 times. The reaction coordinate refers to the distance covered by the SMD atom (shown as a yellow bead) during the course of the pulling experiments. The initial and final structures of an SMD simulation are illustrated on the left and right sides of the figure, respectively. Yellow bead: Y32; Green bead: P34; Iceblue bead: G60; GTP and Cerubidine: Licorice representation. Errors are indicated by the thickness of the curves and are less than 0.3 kcal/mol and 0.1 kcal/mol in ligand-free and ligand-bound simulations, respectively.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79747-fig9-v3.tif"/></fig><fig id="fig9s1" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 1.</label><caption><title>The free energy profile, where the error estimate was calculated by usingbootstrapping.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79747-fig9-figsupp1-v3.tif"/></fig></fig-group></sec><sec id="s2-6"><title>HEK-293T cells were engineered to express HRAS<sup>G12D</sup> mutant</title><p>To investigate G12D-specific system properties in vitro, we established G12D mutant HRAS expressing cell lines. Human embryonic kidney cells (HEK-293T; CRL-11268, ATCC) is a widely used cell line for gene delivery studies due to their high transfection efficiencies (<xref ref-type="bibr" rid="bib74">Ooi et al., 2016</xref>). Accordingly, as proof of concept, we aimed to introduce G12D mutant HRAS into HEK-293T cells (293T-HRAS<sup>G12D</sup>). We firstly subcloned the HRAS<sup>G12D</sup> gene region in the commercially available plasmid with a bacterial expression system into the eukaryotic expression plasmid carrying a puroR gene as a selection marker (See <xref ref-type="fig" rid="fig10">Figure 10A</xref>). Next, we showed that the transfection method reaches a high efficiency (90–95%) when a GFP expressing plasmid is introduced into HEK-293T cells (See <xref ref-type="fig" rid="fig10">Figure 10B</xref>).</p><fig id="fig10" position="float"><label>Figure 10.</label><caption><title>Engineering HEK-293T cells expressing mutant HRAS<sup>G12D</sup>.</title><p>(<bold>a</bold>) Schematic representation of the cloning HRAS<sup>G12D</sup> gene region into the eukaryotic expression plasmid (with PuroR gene to select transgene positive population) using the Gibson Assembly method and engineering HEK-293T cell line to overexpress HRAS<sup>G12D</sup> protein upon transfection followed by puromycin selection. (<bold>b</bold>) Fluorescent images 293T cells transfected with GFP-encoding plasmid. (<bold>c</bold>) RT-PCR analysis showing expression levels of HRAS<sup>G12D</sup> in 293T cells transfected with HRAS<sup>G12D</sup> plasmid. (<bold>d</bold>) ImageJ analysis of band densities from ‘C’. (<bold>e</bold>) Western blot analysis showing expression levels of HRAS<sup>G12D</sup> in 293T-HRAS<sup>G12D</sup> cells. (<bold>f</bold>) ImageJ analysis of western-blot band densities. Data represent the means of three independent assays. Unpaired t-test analysis was used to test the difference between each experimental group and the control group. BF: bright field, FL: Fluorescence, ***: p&lt;0,0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79747-fig10-v3.tif"/></fig><p>A cDNA library of the 293T-HRAS<sup>G12D</sup> cell lysates was obtained for RT-PCR analysis and we detected that the 293T-HRAS<sup>G12D</sup> cells express increased levels of HRAS transcripts compared to control 293T cells (wild-type; cells with no gene transfer) (See <xref ref-type="fig" rid="fig10">Figure 10C and D</xref>). The primer sets can amplify both wild-type and mutant forms of HRAS since there is only one single base difference and no mutant specificity (<xref ref-type="bibr" rid="bib70">Muñoz-Maldonado et al., 2019</xref>). Therefore, we detected HRAS<sup>G12D</sup> expression at the protein level using a G12D specific antibody. Our results showed that the transfected cells (293T-HRAS<sup>G12D</sup>) express significantly high levels of HRAS<sup>G12D</sup> protein compared to wild-type cells (See <xref ref-type="fig" rid="fig10">Figure 10E and F</xref>). Interestingly, we found out that wild-type HEK-293T cells naturally lack G12D mutant protein expressions.</p></sec><sec id="s2-7"><title>Cerubidine treatment selectively inhibits the HRAS<sup>G12D</sup>-RAF interaction and blocks activation of HRAS<sup>G12D</sup></title><p>To study the potential HRAS<sup>G12D</sup>-RAF targeting effects of our proposed small molecule cerubidine, firstly, we determined the optimum doses of the molecule in 293T cell lines. The cells treated with a range of compound concentrations (1, 5, 10, 25, 50, 100 μM) showed 80% viability up to 10 μM treatment. Besides that, 25 μM and above cerubidine treatments were cytotoxic to the cells (See <xref ref-type="fig" rid="fig11">Figure 11</xref>). We then used active RAS pull-down and detection kit (Thermo) to analyze the interaction of the active RAS protein with RAF protein in the presence of cerubidine. To confirm the proper functioning of the kit, we treated 293T cell lysates with GTPγS and GDP in-vitro to activate and inactivate RAS. GTPγS is the non-hydrolyzable or slowly hydrolyzable analog of GTP. RAS is active when interacting with GTP and inactive upon binding of GDP (<xref ref-type="bibr" rid="bib86">Simanshu et al., 2017</xref>). In this context, GTPγS was treated with RAS, which increased the interaction of the RAS protein with RAF by keeping it in its active form (See <xref ref-type="fig" rid="fig12">Figure 12A,B and C</xref>). Following detection of the RAS-RAF interaction, we treated 293T-HRAS<sup>G12D</sup> cells with optimum doses of cerubidine and collected lysate for protein isolation at different time points. We detected a significant decrease in the active RAS<sup>G12D</sup>, especially at the 12<sup>th</sup> hr of treatment. Additionally, we analyzed the presence/decrease of active wild-type HRAS in the same line and there was no significant change in active HRAS levels after cerubidine treatment. Overall data showed that the cerubidine treatment blocks HRAS-RAF interaction in a G12D-specific manner (See <xref ref-type="fig" rid="fig12">Figure 12D, E and F</xref>).</p><fig id="fig11" position="float"><label>Figure 11.</label><caption><title>Cell viability assay in control and 24 hr treated 293T cells.</title><p>The plot indicates the cell viability of 293T cells upon treatment with cerubidine in a dose-dependent manner (1, 5, 10, 25, 50, 100 μM).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79747-fig11-v3.tif"/></fig><fig id="fig12" position="float"><label>Figure 12.</label><caption><title>Cell viability assay in control and 24 hr treated 293T cells.</title><p>(<bold>a</bold>) Scheme to outline the principle of active Ras pull-down reaction. (<bold>b</bold>) Immunoprecipitation (IP) assays show interactions of RAS with RAF proteins in the presence (Lane 1–2) and absence (Lane 3) of GTPγS-GDP. Protein extracts were immunoprecipitated with Raf1-RBD probe and resolved by SDS PAGE. Protein-protein interactions were immunodetected using anti-RAS antibodies. (<bold>c</bold>) ImageJ analysis of Western-blot band densities. Unpaired t-test analysis was used to test the difference between each experimental group and the control group. (<bold>d</bold>) Scheme outlining the RAF1 interacted active HRAS<sup>G12D</sup> precipitation assay. (<bold>e</bold>) Immunoprecipitation (IP) assays showing interactions of RAS with RAF proteins in 293T<sup>HRASG12D++</sup> cells treated with increasing doses (1,5 and 10 μM) of Cerubudine. Protein extracts obtained at different time points (0 hr, 3 hr, and 12 hr) were immunoprecipitated with the RAF1-RBD probe and resolved by SDS-PAGE. Protein-protein interactions were immunodetected using anti-RAS<sup>G12D</sup> and anti-HRAS antibodies (<bold>f</bold>) ImageJ analysis of Western-blot band densities. Unpaired t-test analysis was used to test the difference between each RAS<sup>G12D</sup> group and the HRAS group. **: p&lt;0.001, ***: p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79747-fig12-v3.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Due to involvement in crucial biological processes such as cell growth, proliferation, and differentiation, the RAS protein family has been used as a hot target in drug discovery studies. However, no therapeutic molecule has yet been proven to be used in the clinics due to the absence of deep clefts on the surface of the protein. On the other hand, recently, phosphorylation has been shown to impact the function of the RAS by inhibiting its interaction with effector proteins like RAF, which is involved in the onset of various cancer types. Moreover, examination of the crystal structures pertaining to RAS/RAF complexes showed that Y32 was pointing towards the nucleotide-binding pocket, whereas it was far in the RAF inhibitor-bound RAS protein (PDB ID: 6WGN) (<xref ref-type="bibr" rid="bib111">Zhang et al., 2020</xref>) suggesting that orientational preference of Y32 might control interaction of RAS with RAF (See <xref ref-type="fig" rid="fig13">Figure 13</xref>).</p><fig id="fig13" position="float"><label>Figure 13.</label><caption><title>Depiction of the RAF/RAS interaction interface in the absence/presence of the ligand, cerubidine.</title><p>(<bold>a</bold>) RAF-RBD in complex with HRAS. Y32 and GTP are shown in licorice representation, whereas protein and RAF-RBD interaction interface is shown in New Cartoon, and surface representation, respectively. (<bold>b</bold>) The displacement of Y32 from the nucleotide-binding pocket by cerubidine, which is colored with red, causes steric clash at the RAS/RAF interface.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79747-fig13-v3.tif"/></fig><p>In this study, motivated by these structural and biochemical data we set out to investigate the impact of phosphorylation on dynamics and structure of HRAS<sup>WT</sup>, and aimed to induce similar modulation in the mutant HRAS by means of small therapeutics to prevent interaction with RAF. To this end, we performed extensive MD simulations on the phosphorylated HRAS and showed that the post-translational modification impacted the dynamics of Switch I and also pushed Y32 out of the nucleotide-binding pocket. Importantly, flexibility of Switch I in the mutant RAS provided a possible binding pocket in the vicinity of the nucleotide-binding site which could be targeted by FDA-approved ligands that modulated dynamics of Y32. Moreover, we also showed that displacement of Switch I and Y32 by the ligand was energetically more favorable than in the absence of the ligand.</p><p>Cancer cells show highly mutagenic profile and hard to treat with standard therapies without cancer cell selectivity. Additionaly, in today’s medicine, personalized approaches are ultimately needed considering the individual based differences of the pathology. HRAS mutations are very common in cancer and G12D variant is primarily found in bladder urothelial carcinoma, cutaneous melanoma, infiltrating renal pelvis, ureter urothelial carcinoma, melanoma, and colorectal adenocarcinoma (<xref ref-type="bibr" rid="bib93">The AACR Project GENIE Consortium et al., 2017</xref>). Accordingly, in our study, we showed that cancer specific G12D mutant can be targeted by small molecules to interfere with RAF interaction and eventually RAS inactivation. Targeting HRAS-G12D by small molecules can be adopted to further study cell proliferation/death kinetics considering inhibition of RAF/MEK/ERK signalling. Here, we studied HRAS<sup>G12D</sup>; however, high-sequence conservation and phosphorylation present among RAS isoforms suggest the potential application of the methodology to other members in the RAS protein family. From that perspective, this study does not only provide mechanistic insight into the impact of phosphorylation but also opens up new avenues for possible use of the post-translational modification in future drug discovery studies. Hereby, we suggest further preclinical examination of our hypothesis for biological mechanisms which might potentiate their clinical uses.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Molecular dynamics simulations of GTP-bound HRAS<sup>pY32</sup></title><sec id="s4-1-1"><title>System setup for molecular dynamics simulations</title><p>The crystal structure of phosphoaminophosphonic acid-guanylate ester (GNP)-bound HRAS<sup>WT</sup> (PDB ID: 5P21) (<xref ref-type="bibr" rid="bib76">Pai et al., 1990</xref>) was retrieved from the Protein Data Bank (<ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/">https://www.rcsb.org/</ext-link>) (<xref ref-type="bibr" rid="bib6">Berman, 2000</xref>; <xref ref-type="bibr" rid="bib12">Burley et al., 2019</xref>). In order to prepare its GTP-bound state, the N<sub>3</sub>B atom of GNP was substituted with oxygen atom. The crystal waters, which were located within 5 Å of the nucleotide, were kept in simulations. Following, the GTP-bound form of the protein was protonated at pH 7.4 according to the pKa values obtained from the ProPka server (<xref ref-type="bibr" rid="bib87">Søndergaard et al., 2011</xref>; <xref ref-type="bibr" rid="bib73">Olsson et al., 2011</xref>). The phosphorylation of Y32 residue was made using the TP2 patch provided by CHARMM-GUI server (<xref ref-type="bibr" rid="bib42">Johnson and Lewis, 2001</xref>). The protein, GTP and Mg<sup>2+</sup> ion were parametrized using the CHARMM36m force-field (<xref ref-type="bibr" rid="bib7">Best et al., 2012</xref>) while water molecules were modeled using the TIP3P water model (<xref ref-type="bibr" rid="bib63">Mark and Nilsson, 2001</xref>). The thickness of the water layer was set to 15 Å to take periodic boundary conditions into account. Eventually, the solvated system was neutralized with 0.15 M NaCl.</p></sec><sec id="s4-1-2"><title>Simulation protocol</title><p>The MD simulations were employed via Compute Unified Device Architecture (CUDA) version of NAnoscale Molecular Dynamics (NAMD) (<xref ref-type="bibr" rid="bib97">Vanommeslaeghe et al., 2010</xref>; <xref ref-type="bibr" rid="bib7">Best et al., 2012</xref>; <xref ref-type="bibr" rid="bib98">Vanommeslaeghe and MacKerell, 2012</xref>; <xref ref-type="bibr" rid="bib99">Vanommeslaeghe et al., 2012</xref>; <xref ref-type="bibr" rid="bib110">Yu et al., 2012</xref>; <xref ref-type="bibr" rid="bib88">Soteras Gutiérrez et al., 2016</xref>), in which the graphical processing unit acceleration was enabled. Temperature, pressure, and time step were set to 310 K, 1 atm, 2 femtoseconds, respectively. In order to calculate the long-range electrostatic interactions, the particle mesh Ewald method was used (<xref ref-type="bibr" rid="bib19">Darden, 1993</xref>; <xref ref-type="bibr" rid="bib25">Essmann et al., 1995</xref>). For computation of non-bonded interactions, the cut-off value was adjusted to 12 Å. Moreover, the prepared system was minimized for 2400 time steps. After minimization, the GTP-bound HRAS<sup>pY32</sup> system was simulated in the NPT ensemble. Four simulations were performed per each system studied, each of which started with a different velocity distribution. We performed at least <italic>ca</italic>. 1 μs per each replicate of the system except some ligand-bound systems. For those, when the opening of Switch I was observed the simulation continued additional <italic>ca</italic>. 200 ns and then ended. Obtained trajectories were analyzed by combining these four replicates. Also, time-line data per each replicate is provided as the supplementary information (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>, and <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>).</p></sec></sec><sec id="s4-2"><title>Ensemble-based virtual screening</title><sec id="s4-2-1"><title>Clustering the trajectory pertaining to HRAS<sup>G12D</sup>, identification of possible binding pockets, and determination of pharmacophore groups</title><p>The most probable conformational state of the binding pocket pertaining to HRAS<sup>G12D</sup> was determined by using following reaction coordinates: distance measured between (i) side-chain oxygen of residue T35 and Pγ atom of GTP, (ii) backbone amide of the residue G60 and Pγ atom of GTP, which were used to point out different conformational states of the nucleotide-bindng pocket in our previous study (<xref ref-type="bibr" rid="bib39">Ilter and Sensoy, 2019</xref>). The frames, which represent different conformational states of the nucleotide-binding pocket with respect to the above-mentioned coordinates, were selected. Subsequently, GTP and Mg<sup>2+</sup> were removed from the frames and proteins were optimized using the OPLS3e force-field (<xref ref-type="bibr" rid="bib81">Roos et al., 2019</xref>) that is available in the ‘Protein Preparation’ module of the Schrödinger software (<xref ref-type="bibr" rid="bib84">Sastry et al., 2013</xref>; <xref ref-type="bibr" rid="bib80">Release, 2018</xref>; <xref ref-type="bibr" rid="bib81">Roos et al., 2019</xref>). The optimized structures were provided as inputs to the ‘SiteMap’ module of the Schrödinger (<xref ref-type="bibr" rid="bib33">Halgren, 2007</xref>; <xref ref-type="bibr" rid="bib34">Halgren, 2009</xref>; <xref ref-type="bibr" rid="bib80">Release, 2018</xref>). Subsequently, possible binding pockets having higher scores were identified and utilized in further steps. Afterwards, pharmacophore groups were built up in accordance with chemical and geometrical properties of the identified binding pockets. To do so, the ‘Develop Pharmacophore Model’ module of Schrödinger was utilized (<xref ref-type="bibr" rid="bib83">Salam et al., 2009</xref>; <xref ref-type="bibr" rid="bib58">Loving et al., 2009</xref>). Following, candidate molecules, which include at least 3 of the 7 pharmacophore features and have molecular weight less than 550 kDa, were sought in the BindingDB (<xref ref-type="bibr" rid="bib29">Gilson et al., 2016</xref>; <xref ref-type="bibr" rid="bib57">Liu et al., 2007</xref>; <xref ref-type="bibr" rid="bib15">Chen et al., 2001b</xref>; <xref ref-type="bibr" rid="bib14">Chen et al., 2001a</xref>; <xref ref-type="bibr" rid="bib16">Chen et al., 2002</xref>, DrugCentral <xref ref-type="bibr" rid="bib96">Ursu et al., 2019</xref>; <xref ref-type="bibr" rid="bib95">Ursu et al., 2017</xref>, NCGC <xref ref-type="bibr" rid="bib36">Huang et al., 2011</xref>, and DrugBank <xref ref-type="bibr" rid="bib105">Wishart et al., 2018</xref>; <xref ref-type="bibr" rid="bib54">Law et al., 2014</xref>; <xref ref-type="bibr" rid="bib51">Knox et al., 2011</xref>; <xref ref-type="bibr" rid="bib104">Wishart et al., 2008</xref>; <xref ref-type="bibr" rid="bib103">Wishart et al., 2006</xref> databases).</p></sec></sec><sec id="s4-3"><title>Testing the stability of ligand-HRAS<sup>G12D</sup> complexes via atomistic simulations</title><p>After the selection of candidates based on their GScore values and orientations next to the nucleotide-binding pocket, the stability and the impact of the ligands on the structure and dynamics of HRAS<sup>G12D</sup> were explored by means of MD simulations. To this end, the topology and parameter files of the candidate molecules were prepared using the ‘Ligand Reader &amp; Modeler’ of CHARMM-GUI (<xref ref-type="bibr" rid="bib41">Jo et al., 2008</xref>; <xref ref-type="bibr" rid="bib49">Kim et al., 2017</xref>). The systems were simulated using at least two replicates, each of which started with different initial velocity distribution under the same conditions that were used for HRAS<sup>pY32</sup>.</p></sec><sec id="s4-4"><title>Local and global analysis of the trajectories</title><p>The trajectories were visualized with the ‘Visual Molecular Dynamics’ (VMD) and snapshots were rendered using the ‘Taychon Render’ (<xref ref-type="bibr" rid="bib37">Humphrey et al., 1996</xref>; <xref ref-type="bibr" rid="bib90">Stone, 1998</xref>). ‘Groningen Machine for Chemical Simulations’ (GROMACS) package and ProDy library were utilized for the local and global trajectory analysis (<xref ref-type="bibr" rid="bib1">Abraham et al., 2015</xref>; <xref ref-type="bibr" rid="bib56">Lindahl and van der Spoel, 2021</xref>; <xref ref-type="bibr" rid="bib4">Bakan et al., 2011</xref>). Data were visualized using the Seaborn and Matplotlib libraries <xref ref-type="bibr" rid="bib38">Hunter, 2007</xref>.</p><sec id="s4-4-1"><title>Root-mean-square fluctuation</title><p>The root-mean-square fluctuation (RMSF) of backbone atoms throughout the obtained trajectories was calculated using the ‘gmx rmsf’ module of GROMACS (<xref ref-type="bibr" rid="bib1">Abraham et al., 2015</xref>; <xref ref-type="bibr" rid="bib56">Lindahl and van der Spoel, 2021</xref>) as shown in the below formula;<disp-formula id="equ1"><label>(1)</label><mml:math id="m1"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">R</mml:mi></mml:mrow><mml:mi>M</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo>=</mml:mo><mml:msqrt><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>T</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:munderover><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">i</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:mover><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">t</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo accent="false">¯</mml:mo></mml:mover><mml:mo stretchy="false">)</mml:mo></mml:msqrt></mml:mrow></mml:math></disp-formula></p><p>where <italic>T</italic> and <italic>R<sub>i</sub>(t</italic>) correspond to the duration of simulation and coordinates of backbone atom <italic>R<sub>i</sub></italic> at time <italic>t</italic>, respectively. By courtesy of this, the flexibility of each residue was computed, and made a holistic comparison with the systems. Particularly, for uncovering the impact of ligands on the backbone RMSF of Y32 and RAF interaction interfaces, the backbone RMSF value of the regions/residues of interest pertaining to ligand-bound HRAS<sup>G12D</sup> was subtracted from those of HRAS<sup>G12D</sup>.</p></sec><sec id="s4-4-2"><title>probability distribution</title><p>The probability density distributions of atom-pair distances were exploited to have a closer look into the impact of the tyrosyl phosphorylation on HRAS<sup>WT</sup> as well as the impact of candidate molecules on HRAS<sup>G12D</sup>. To this end, the ‘gmx distance’ module of GROMACS was utilized for measuring the distance (i) between the Cα atoms of G/D12 and P34, and (ii) between the side-chain oxygen atom of Y32—OH—and Pγ atom of GTP (<xref ref-type="bibr" rid="bib1">Abraham et al., 2015</xref>; <xref ref-type="bibr" rid="bib56">Lindahl and van der Spoel, 2021</xref>). The computed raw-data was converted into normalized probability density distribution plots by calculating the frequencies of the sampled distances adjusting the sampling range as 1Å via Matplotlib’ library <xref ref-type="bibr" rid="bib38">Hunter, 2007</xref>. As a side note, the sampling range of angle was set to 20°.</p><p>The probability density distribution of the distance between (i) the Oγ atom of T35 and Pγ of GTP, (ii) the backbone amide of G60 and Pγ of GTP, and (iii) Oε atom of Q61 and Pγ of GTP were also drawn. In addition to the interatomic distances, the probability density distribution of <inline-formula><mml:math id="inf8"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>χ</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula><sub>2</sub> pertaining to pY32 was also calculated.</p></sec></sec><sec id="s4-5"><title>Number of water molecules</title><p>The number of water molecules around the GTP was calculated over the course of produced trajectories to reveal the impact of mutation, tyrosyl phosphorylation, and ligands on the exposure of GTP to the possible nucleophilic water attacks via the ProDy library (<xref ref-type="bibr" rid="bib4">Bakan et al., 2011</xref>). To this end, the water molecules within 5 Å of GTP were selected and computed per frame. Thereafter, the mean of the number of water molecules around GTP was taken as well as the standard error of the mean was calculated.</p></sec><sec id="s4-6"><title>Principal component analysis</title><p>In addition to the local dynamics and structural properties of the phosphorylated system, its overall dynamics were also scrutinized via principal component analysis (PCA). The principal components of HRAS<sup>pY32</sup> were compared with those of HRAS<sup>WT</sup>, and HRAS<sup>G12D</sup>. By doing so, the collective effect of the tyrosyl phosphorylation was demystified. In this regard, the trajectory of HRAS<sup>pY32</sup> was aligned with respect to the Cα atoms of the reference structure, and subsequently, a diagonalized co-variance matrix was generated;<disp-formula id="equ2"><label>(2)</label><mml:math id="m2"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="italic">C</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">j</mml:mi><mml:mi mathvariant="sans-serif">k</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo fence="false" stretchy="false">⟨</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">j</mml:mi><mml:mi mathvariant="sans-serif">k</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">j</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">k</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo fence="false" stretchy="false">⟩</mml:mo></mml:mrow></mml:math></disp-formula></p><p>where <italic>M<sub>jk</sub>Δ r<sub>j</sub>Δ r<sub>k</sub></italic> corresponds to displacement from time-averaged structure for each coordinate of <italic>j</italic> and <italic>k</italic> atoms, whilst co-variance matrix is abbreviated by <italic>C<sub>jk</sub></italic>.</p><p>Following the generation of the diagonalized co-variance matrix, eigenvectors (<italic>v</italic>) and eigenvalues (<inline-formula><mml:math id="inf9"><mml:mi>δ</mml:mi></mml:math></inline-formula><sup><italic>2</italic></sup>) were calculated.<disp-formula id="equ3"><label>(3)</label><mml:math id="m3"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="italic">C</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">j</mml:mi><mml:mi mathvariant="sans-serif">k</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mi>δ</mml:mi><mml:mrow><mml:mrow><mml:mn mathvariant="sans-serif">2</mml:mn></mml:mrow></mml:mrow></mml:msup><mml:mi>v</mml:mi></mml:mrow></mml:math></disp-formula></p><p>The diagonalized co-variance matrix was generated using the ‘gmx covar’ module of GROMACS (<xref ref-type="bibr" rid="bib1">Abraham et al., 2015</xref>; <xref ref-type="bibr" rid="bib56">Lindahl and van der Spoel, 2021</xref>). Thereafter, the ‘gmx anaeig’ module of GROMACS was made use of taking the projection of the trajectory with respect to the eigenvectors of interest, which eventually illuminated the collective spatial organization of the protein as well as the eigen RMSF values of the Cα atoms (<xref ref-type="bibr" rid="bib1">Abraham et al., 2015</xref>; <xref ref-type="bibr" rid="bib56">Lindahl and van der Spoel, 2021</xref>).</p></sec><sec id="s4-7"><title>Perturb-scan-pull</title><p>PSP consists of three parts, which are PRS, steered molecular dynamics (SMD), and potential of mean force (PMF) calculation (<xref ref-type="bibr" rid="bib40">Jalalypour et al., 2020</xref>). Firstly, the PRS calculation of all the ligand-bound systems were conducted, whilst the SMD and PMF calculation were carried out for the cerubidine-bound HRAS<sup>G12D</sup> system, whose dynamic and structural properties are similar to those of other studied ligand-bound systems as elucidated by atomistic simulations.</p><sec id="s4-7-1"><title>Perturbation-response scanning</title><p>PRS was performed to achieve the target states by perturbing each residues on the initial state, which, in turn, provided insight into the response of all residues in the HRAS<sup>G12D</sup>. In this way, the residues, which play a pivotal role in the anticipated transitions, were aimed to be identified. To this end, the spatial position of both Switch I and II was clustered to determine initial and target states by measuring the distance between (i)the Cα atoms of D12 and P34 and (ii) the backbone amide of G60 and Pγ of GTP over the course of trajectories pertaining to HRAS<sup>G12D</sup> and ligand-bound HRAS<sup>G12D</sup>. Following, the coarse-grain representation of each state was modeled by selecting the center of mass of the Cα atom pertaining to each residue as a node. Herein, 1000 random forces (ΔF) in distinct directions were sequentially exerted on each node in order to perturb the initial structure (<xref ref-type="bibr" rid="bib3">Atilgan and Atilgan, 2009</xref>). In light of the linear response theory, displacement (ΔR) as a response to force exerted on the structure was derived from an equilibrated chunk of MD simulations;<disp-formula id="equ4"><label>(4)</label><mml:math id="m4"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:msub><mml:mrow><mml:mi mathvariant="bold">R</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mn mathvariant="sans-serif">1</mml:mn></mml:mrow></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo fence="false" stretchy="false">⟨</mml:mo><mml:mrow><mml:mi mathvariant="bold">R</mml:mi></mml:mrow><mml:msub><mml:mo fence="false" stretchy="false">⟩</mml:mo><mml:mrow><mml:mrow><mml:mn mathvariant="sans-serif">1</mml:mn></mml:mrow></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mo fence="false" stretchy="false">⟨</mml:mo><mml:mrow><mml:mi mathvariant="bold">R</mml:mi></mml:mrow><mml:msub><mml:mo fence="false" stretchy="false">⟩</mml:mo><mml:mrow><mml:mrow><mml:mn mathvariant="sans-serif">0</mml:mn></mml:mrow></mml:mrow></mml:msub><mml:mo>≅</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">B</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mi>T</mml:mi></mml:mrow></mml:mfrac></mml:mstyle><mml:mo fence="false" stretchy="false">⟨</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mi mathvariant="bold">R</mml:mi></mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:msup><mml:mrow><mml:mi mathvariant="bold">R</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">T</mml:mi></mml:mrow></mml:mrow></mml:msup><mml:msub><mml:mo fence="false" stretchy="false">⟩</mml:mo><mml:mrow><mml:mrow><mml:mn mathvariant="sans-serif">0</mml:mn></mml:mrow></mml:mrow></mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mi mathvariant="bold">F</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">B</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mi>T</mml:mi></mml:mrow></mml:mfrac></mml:mstyle><mml:mrow><mml:mi mathvariant="bold">C</mml:mi></mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mi mathvariant="bold">F</mml:mi></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>where R<sub>0</sub> and R<sub>1</sub> correspond to the unperturbed initial state of HRAS<sup>G12D</sup> and perturbed predicted coordinates, respectively;<disp-formula id="equ5"><label>(5)</label><mml:math id="m5"><mml:mrow><mml:mrow><mml:mi mathvariant="bold">C</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mo fence="false" stretchy="false">⟨</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mi mathvariant="bold">R</mml:mi></mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:msup><mml:mrow><mml:mi mathvariant="bold">R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">T</mml:mi></mml:mrow></mml:msup><mml:msub><mml:mo fence="false" stretchy="false">⟩</mml:mo><mml:mrow><mml:mrow><mml:mn mathvariant="sans-serif">0</mml:mn></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula></p><p>where the cross-correlation of the fluctuations of the nodes in the initial state is denoted by C.<disp-formula id="equ6"><label>(6)</label><mml:math id="m6"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="italic">O</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">i</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:msup><mml:mrow><mml:mi mathvariant="bold">R</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">i</mml:mi></mml:mrow></mml:mrow></mml:msup><mml:mo>⋅</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mi mathvariant="bold">S</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mo stretchy="false">∣</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mi mathvariant="bold">R</mml:mi></mml:mrow><mml:mo>⋅</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mi mathvariant="bold">R</mml:mi></mml:mrow><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mi mathvariant="sans-serif">i</mml:mi></mml:mrow></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mi mathvariant="bold">S</mml:mi></mml:mrow><mml:mo>⋅</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mi mathvariant="bold">S</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:msup><mml:mo stretchy="false">∣</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula></p><p>The measured difference between the initial and target structures and the overlap between two nodes are denoted by ΔS and <italic>O<sup>i</sup></italic>, respectively.</p></sec><sec id="s4-7-2"><title>Steered molecular dynamics</title><p>Following the PRS calculation, SMD simulations were employed under the same circumstances as the above-mentioned MD simulations pertaining to HRAS<sup>pY32</sup>. The set of external poses were imposed to the Cα atom of Y32, where the constant velocity and spring constant were adjusted to 0.03 Å ps<sup>–1</sup> and 90 kcal mol<sup>–1</sup>Å<sup>–2</sup>, respectively. Moreover, the Cα atoms of L23 and R149 residues were fixed along the pulling direction so as to prevent dislocation and rotation on the structure. The SMD runs were considered completed as long as the secondary structure of the protein was maintained and the final structure resembled the target conformation. With the time step of the simulations of 2 fs, this leads to covering a distance of ca. 40 Å in the pulling direction in ca. 3 ns. Data were recorded every 12 steps for further processing.</p></sec><sec id="s4-7-3"><title>Potential of mean force</title><p>The energy landscape of the transition in either presence or lack of the drug molecule, namely cerubudine, was elaborated by calculating the PMF along the pulling direction. Considering the well-established procedure (<xref ref-type="bibr" rid="bib40">Jalalypour et al., 2020</xref>), the PMF was computed according to the second-order cumulant expansion formula via,<disp-formula id="equ7"><label>(7)</label><mml:math id="m7"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="italic">F</mml:mi></mml:mrow><mml:mrow><mml:mi>λ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>λ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo fence="false" stretchy="false">⟨</mml:mo><mml:mi>W</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo fence="false" stretchy="false">⟩</mml:mo><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>2</mml:mn><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">B</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mi>T</mml:mi></mml:mrow></mml:mfrac><mml:mo stretchy="false">(</mml:mo><mml:mo fence="false" stretchy="false">⟨</mml:mo><mml:mi>W</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mrow><mml:mn mathvariant="sans-serif">2</mml:mn></mml:mrow></mml:mrow></mml:msup><mml:mo fence="false" stretchy="false">⟩</mml:mo><mml:mo>−</mml:mo><mml:mo fence="false" stretchy="false">⟨</mml:mo><mml:mi>W</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:msup><mml:mo fence="false" stretchy="false">⟩</mml:mo><mml:mrow><mml:mrow><mml:mn mathvariant="sans-serif">2</mml:mn></mml:mrow></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mo>.</mml:mo><mml:mo>.</mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>For either of the ceribudine-bound and ceribudine-free systems, 70 SMD simulations were conducted. The resulting trajectories were monitored so as to ensure they did not diverge from the intended path. In the ceribudine-bound systems, all trajectories stayed on the path, while the 9 simulations that diverged were discarded from the analyses in the ligand-free simulations. Curves were calculated by binning the displacement vs. force data, each projected on the pulling direction at intervals of 24 fs, into reaction coordinate distances of size 0.4 Å. Error bars were calculated by block averaging the data in each bin as well as bootstrapping (see <xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1</xref>). SMD data and the programs used in their analyses are accessible at <ext-link ext-link-type="uri" xlink:href="https://github.com/midstlab/PMF_from_SMD_data/">https://github.com/midstlab/PMF_from_SMD_data/</ext-link>, (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:76cffa3df2bfd8edae4a92604cb0df1187398d6b;origin=https://github.com/midstlab/PMF_from_SMD_data;visit=swh:1:snp:172d53637b2f0b6ada90eeeea7dd46b59c59a824;anchor=swh:1:rev:f72f6cbe253ddc4515b47f670eb936a50adc7824">swh:1:rev:f72f6cbe253ddc4515b47f670eb936a50adc7824</ext-link>; <xref ref-type="bibr" rid="bib67">MIDST lab, 2022</xref>).</p></sec></sec><sec id="s4-8"><title>Preparation of plasmid constructs encoding HRAS<sup>G12D</sup></title><p>The bacterial expression plasmid Hs.HRAS<sup>G12D</sup> (83183) was obtained from Addgene (U.S). The mutant HRAS<sup>G12D</sup> was then inserted between the BamHI and BlpI restriction sites under the (UbC promoter) into the lentiviral vectors with the PuroR gene. (The vector was a kind gift from Dr. Shah (Brigham and Woman’s Hospital, Harvard Medical School, Boston, U.S.) and was previously characterized and widely studied <xref ref-type="bibr" rid="bib91">Stuckey et al., 2015</xref>).</p></sec><sec id="s4-9"><title>Engineering HRAS<sup>G12D</sup> expressing HEK-293T cells; 293T-HRAS<sup>G12D</sup></title><p>To investigate the in vitro outcomes of our in silico findings, HEK-293T cells (CRL-11268, ATCC) were engineered to express mutant HRAS<sup>G12D</sup>. HEK-293T cell lines cultured on T75 flask with high-glucose DMEM medium which contains 10% fetal bovine serum (FBS), 1% Penicillin Streptomycin at 37 °C in 5% CO<sub>2</sub> incubator. One day (18–24 hr) prior to transfection, cells were seeded at an optimum density that reaches 70–80% confluency the next day, at the time of transfection. Plasmid DNA was transfected into cells using Trans-Hi In Vitro DNA Transfection Reagent (F90101TH, FormuMax) according to the manufacturer’s recommendations. 12–18 hr after transfection, the medium containing the Trans-Hi/DNA complex was removed and replaced with a fresh whole serum/antibiotic-containing medium.</p></sec><sec id="s4-10"><title>HRAS<sup>G12D</sup> expression analysis</title><p>To use 293T-HRAS<sup>G12D</sup> cells in the following experiments, first of all, we analyzed the overexpression of HRAS transcripts by reverse transcriptase-polymerase chain reaction(RT-PCR). The primer sets can not be specific to the mutant G12D since there is only 1 single base difference in G12D mutant versus wild-type HRAS. For this reason, we further evaluated G12D expression at the protein level via western blot.</p><sec id="s4-10-1"><title>RT-PCR</title><p>To verify increased HRAS transcript levels in HEK-293T cells by RT-PCR, we firstly harvested cells expressing HRAS<sup>WT</sup> and HRAS<sup>G12D</sup> to prepare RNA samples. Afterward, RNA was extracted using RNeasy Mini Kit (74104, Qiagen) and the cDNA library was prepared from 1 μg of total RNA, using SuperScript VILO cDNA Synthesis kit (11754050, Invitrogen). HRAS was then amplified by RT-PCR using a standard PCR protocol on a T100 Thermal Cycler (BIO-RAD). Gene expression was normalized to that of a housekeeping gene; GAPDH (glyceraldehyde-3-phosphate dehydrogenase). The primer sets (5’–3’) used for RT-PCR were as follows:</p><p><italic>GAPDH: <named-content content-type="sequence">Fw- GTCAGTGGTGGACCTGACCT</named-content>; <named-content content-type="sequence">Rv- TGCTGTAGCCAAATTCGTTG</named-content></italic> (245 bp PCR product) and <italic>HRAS: <named-content content-type="sequence">Fw- GGATCCATGACGGAATATAAGCTGG</named-content>; <named-content content-type="sequence">Rv- GCTCAGCTTAGGAGAGCACACACTTGC</named-content></italic> (570 bp PCR product).</p></sec><sec id="s4-10-2"><title>Protein sample preparation</title><p>Cells were washed two times with ice-cold phosphate-buffered saline (PBS) prior to 1 X lysis buffer (25 mM Tris-HCl,150 mM NaCl, 5 mM MgCl<sub>2</sub>,1%NP-40, and 5% glycerol) involving complete Mini Protease Inhibitor Cocktail tablet (11836153001, Roche). Lysates were spun at 16,000×g for 15 min and the supernatants were reserved as protein samples. The Pierce BCA Protein Assay Reagent (23227, Thermo Fisher Scientific) was used to quantify the protein concentration of each sample.</p></sec><sec id="s4-10-3"><title>Western blot (WB) analysis</title><p>Cell lysates were resolved by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) using Bolt 4 to 12%, Bis-Tris, 1.0 mm, Mini Protein gel (NW04120BOX, Invitrogen). Proteins were transferred into nitrocellulose membrane by iBlot 2 Dry Blotting System (Invıtrogen) at constant current of 1.3 A for 7 min. Membranes were blocked with 5% BSA-ALBUMIN in Tris-buffered saline/0.1% Tween-20 for 1 hr at room temperature and incubated overnight with rabbit anti-RAS<sup>G12D</sup> (mutant specific) (14429, Cell Signaling Technology) antibody. After primary antibody incubation, membranes were washed with TBST (Tris-buffered saline with 0.05% Tween-20). Secondary antibody (R-05071–500, Advansta), HRP conjugated goat anti-rabbit was diluted to 1:3000 in 5% BSA and incubated for 1 hr at room temperature. Membranes were developed using ECL substrate (1705061, Bio-Rad) and a chemiluminescence signal was detected by Chemidoc (Bio-Rad). Next, β-actin levels were determined as loading controls. For this, the membrane was incubated in stripping buffer (0.2 M Glycine, 0.10% Tween-20, pH:2.5) and blocking solution before reprobing with anti-β-actin (3700, Cell Signaling Technology).</p></sec></sec><sec id="s4-11"><title>Optimization of optimum cerubidine treatment doses to target HRAS<sup>G12D</sup>-RAF interaction</title><p>HEK-293T cells were plated at 5000 cells/well into 96 black well plates (3603, Corning) and cultured in DMEM, high glucose (Gibco) containing 10% FBS at 37 °C in 5% CO2. Cells were cultured overnight and the compounds (dissolved in DMSO) were added to the cells at concentrations ranging from 0 to 100 μM. The cells were incubated under standard culture conditions for 24 hr. Cell viability was quantified using the CellTiterGlo Luminescent Cell Viability Assay (Promega) according to the manufacturer’s instructions to measure ATP generated by metabolically active cells. Luminescent signals were measured using the SpectraMAX (Molecular Devices). The luminescence signals obtained from the compound-treated cells were normalized against the signal for DMSO-only treated cells.</p></sec><sec id="s4-12"><title>Active RAS pull-down assay</title><p>In this experimental setup, we conceptually investigated &quot;G12D versus wild-type&quot; HRAS presence in the active RAS population in the cells treated with cerubidine. RAS activity was determined using Active RAS Pull-Down and Detection Kit (Thermo Fisher Scientific) following the manufacturer’s instructions. Firstly, we tested the assay validity using provided supplements. Lysates were incubated with glutathione S-transferase fusion of the RAS binding domain (RBD) of RAF1 along with glutathione agarose for 1 hr. Agarose beads were collected by centrifugation and washed three times with 1 X Wash Buffer (25 mM Tris-HCl,150 mM NaCl, 5 mM MgCl<sub>2</sub>,1%NP-40, and 5%glycerol). Each sample was resuspended and boiled at 100 °C for 5 min. Samples were analyzed by western blotting as previously described. Analysis of RBD pull-down lysates was performed with mouse anti-RAS Antibody (16117, Thermo Fisher Scientific). Secondly, we prepared cell lysates from cerubidine treated 293T-HRAS<sup>G12D</sup> cells. One day prior to treatment plated a sufficient number of cells so that the cell density reaches the optimal confluency (60–70%) at the time of treatment. Cells were incubated with increased cerubidine concentrations (1, 5, and 10 μM) for 3 hr and 12 hr (0 hr was used as control). After incubation, the active Ras pull-down assay was performed with proteins isolated from the treated and untreated cells (as described above in the protein sample preparation section). Finally, samples were subjected to western blotting as previously described. RBD pull-down lysates were probed with mouse anti-HRAS (sc-29, Santa Cruz Biotechnology), and rabbit anti-RAS<sup>G12D</sup> Mutant Specific antibodies (14429, Cell Signaling Technology).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Supervision, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Methodology</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Supervision, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Supervision, Funding acquisition, Investigation, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-79747-mdarchecklist1-v3.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Result of the analyses for the number of water molecules, PRS calculations and total simulation time for ligand-mutant HRAS trajectories.</title><p>a The average number of water molecules within 5 Å of GTP were calculated over the course of the ligand-bound HRAS<sup>G12D</sup> systems. b Total simulation time performed for ligand- HRAS<sup>G12D</sup> complexes and changes in the backbone RMSF profiles of cerubidine-, tranilast-, nilotinib-, and epirubicin-bound HRAS<sup>G12D</sup> systems with respect to those of HRAS<sup>G12D</sup>. c The results of PRS calculations for the transition between initial and target states.</p></caption><media xlink:href="elife-79747-supp1-v3.zip" mimetype="application" mime-subtype="zip"/></supplementary-material><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Raw unedited gel.</title></caption><media xlink:href="elife-79747-data1-v3.zip" mimetype="application" mime-subtype="zip"/></supplementary-material><supplementary-material id="sdata2"><label>Source data 2.</label><caption><title>Uncropped gels with relevant bands that are clearly labelled.</title></caption><media xlink:href="elife-79747-data2-v3.zip" mimetype="application" mime-subtype="zip"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Simulated data used to generate the figures in the commentary are available at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.17605/OSF.IO/Z2Y5S">https://doi.org/10.17605/OSF.IO/Z2Y5S</ext-link>.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Ilter</surname><given-names>M</given-names></name><name><surname>Kasmer</surname><given-names>R</given-names></name><name><surname>Jalalypour</surname><given-names>F</given-names></name><name><surname>Atilgan</surname><given-names>C</given-names></name><name><surname>Topcu</surname><given-names>O</given-names></name><name><surname>Karakas</surname><given-names>N</given-names></name><name><surname>Sensoy</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Inhibition of mutant RAS-RAF interaction by mimicking structural and dynamic properties of phosphorylated RAS</data-title><source>Open Science Framework</source><pub-id pub-id-type="doi">10.17605/OSF.IO/Z2Y5S</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>MI and OS thank TUBITAK and TUSEB for providing funding in the scope of 2209 A Undergraduate Research Support Program, reference number: 1919B011701434, and Computational Structural Biology Strategic R&amp;D Project Call, reference number: 2019-TA-02–3561, respectively. CA thanks for partial support from TUBITAK, project no. 116F229. MI and OS also acknowledge Istanbul Medipol University for providing access to the High-Performance Computing System so as to run some of the MD simulations. MI, OS, FJ, and CA thank TUBITAK ULAKBIM for giving access to High Performance and Grid Computing Center (TRUBA resources) to complete the rest of the numerical calculations reported in this paper. NK thanks to Dr. Khalid Shah from Brigham and Woman’s Hospital, Harvard Medical School, U.S. for the plasmid backbones.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname><given-names>MJ</given-names></name><name><surname>Murtola</surname><given-names>T</given-names></name><name><surname>Schulz</surname><given-names>R</given-names></name><name><surname>Páll</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>JC</given-names></name><name><surname>Hess</surname><given-names>B</given-names></name><name><surname>Lindahl</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers</article-title><source>SoftwareX</source><volume>1–2</volume><fpage>19</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.softx.2015.06.001</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Araki</surname><given-names>M</given-names></name><name><surname>Shima</surname><given-names>F</given-names></name><name><surname>Yoshikawa</surname><given-names>Y</given-names></name><name><surname>Muraoka</surname><given-names>S</given-names></name><name><surname>Ijiri</surname><given-names>Y</given-names></name><name><surname>Nagahara</surname><given-names>Y</given-names></name><name><surname>Shirono</surname><given-names>T</given-names></name><name><surname>Kataoka</surname><given-names>T</given-names></name><name><surname>Tamura</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Solution structure of the state 1 conformer of GTP-bound H-Ras protein and distinct dynamic properties between the state 1 and state 2 conformers</article-title><source>The Journal of Biological Chemistry</source><volume>286</volume><fpage>39644</fpage><lpage>39653</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.227074</pub-id><pub-id pub-id-type="pmid">21930707</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atilgan</surname><given-names>C</given-names></name><name><surname>Atilgan</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Perturbation-response scanning reveals ligand entry-exit mechanisms of ferric binding protein</article-title><source>PLOS Computational Biology</source><volume>5</volume><elocation-id>e1000544</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1000544</pub-id><pub-id pub-id-type="pmid">19851447</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakan</surname><given-names>A</given-names></name><name><surname>Meireles</surname><given-names>LM</given-names></name><name><surname>Bahar</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>ProDy: protein dynamics inferred from theory and experiments</article-title><source>Bioinformatics</source><volume>27</volume><fpage>1575</fpage><lpage>1577</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btr168</pub-id><pub-id pub-id-type="pmid">21471012</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbacid</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Ras genes</article-title><source>Annual Review of Biochemistry</source><volume>56</volume><fpage>779</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1146/annurev.bi.56.070187.004023</pub-id><pub-id pub-id-type="pmid">3304147</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>HM</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The protein data bank</article-title><source>Nucleic Acids Research</source><volume>28</volume><fpage>235</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1093/nar/28.1.235</pub-id><pub-id pub-id-type="pmid">10592235</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Best</surname><given-names>RB</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Shim</surname><given-names>J</given-names></name><name><surname>Lopes</surname><given-names>PEM</given-names></name><name><surname>Mittal</surname><given-names>J</given-names></name><name><surname>Feig</surname><given-names>M</given-names></name><name><surname>Mackerell</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Optimization of the additive charmm all-atom protein force field targeting improved sampling of the backbone φ, ψ and side-chain χ(1) and χ(2) dihedral angles</article-title><source>Journal of Chemical Theory and Computation</source><volume>8</volume><fpage>3257</fpage><lpage>3273</lpage><pub-id pub-id-type="doi">10.1021/ct300400x</pub-id><pub-id pub-id-type="pmid">23341755</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourne</surname><given-names>HR</given-names></name><name><surname>Sanders</surname><given-names>DA</given-names></name><name><surname>McCormick</surname><given-names>F</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>The GTPase superfamily: conserved structure and molecular mechanism</article-title><source>Nature</source><volume>349</volume><fpage>117</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1038/349117a0</pub-id><pub-id pub-id-type="pmid">1898771</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>S</given-names></name><name><surname>Tänzel</surname><given-names>V</given-names></name><name><surname>Wolf</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Ligand unbinding pathway and mechanism analysis assisted by machine learning and graph methods</article-title><source>Journal of Chemical Information and Modeling</source><volume>62</volume><fpage>4591</fpage><lpage>4604</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.2c00634</pub-id><pub-id pub-id-type="pmid">36176219</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buhrman</surname><given-names>G</given-names></name><name><surname>Holzapfel</surname><given-names>G</given-names></name><name><surname>Fetics</surname><given-names>S</given-names></name><name><surname>Mattos</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Allosteric modulation of ras positions q61 for a direct role in catalysis</article-title><source>PNAS</source><volume>107</volume><fpage>4931</fpage><lpage>4936</lpage><pub-id pub-id-type="doi">10.1073/pnas.0912226107</pub-id><pub-id pub-id-type="pmid">20194776</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bunda</surname><given-names>S</given-names></name><name><surname>Heir</surname><given-names>P</given-names></name><name><surname>Srikumar</surname><given-names>T</given-names></name><name><surname>Cook</surname><given-names>JD</given-names></name><name><surname>Burrell</surname><given-names>K</given-names></name><name><surname>Kano</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Zadeh</surname><given-names>G</given-names></name><name><surname>Raught</surname><given-names>B</given-names></name><name><surname>Ohh</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Src promotes gtpase activity of ras via tyrosine 32 phosphorylation</article-title><source>PNAS</source><volume>111</volume><fpage>E3785</fpage><lpage>E3794</lpage><pub-id pub-id-type="doi">10.1073/pnas.1406559111</pub-id><pub-id pub-id-type="pmid">25157176</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burley</surname><given-names>SK</given-names></name><name><surname>Berman</surname><given-names>HM</given-names></name><name><surname>Bhikadiya</surname><given-names>C</given-names></name><name><surname>Bi</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Di Costanzo</surname><given-names>L</given-names></name><name><surname>Christie</surname><given-names>C</given-names></name><name><surname>Dalenberg</surname><given-names>K</given-names></name><name><surname>Duarte</surname><given-names>JM</given-names></name><name><surname>Dutta</surname><given-names>S</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Goodsell</surname><given-names>DS</given-names></name><name><surname>Green</surname><given-names>RK</given-names></name><name><surname>Guranovic</surname><given-names>V</given-names></name><name><surname>Guzenko</surname><given-names>D</given-names></name><name><surname>Hudson</surname><given-names>BP</given-names></name><name><surname>Kalro</surname><given-names>T</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Lowe</surname><given-names>R</given-names></name><name><surname>Namkoong</surname><given-names>H</given-names></name><name><surname>Peisach</surname><given-names>E</given-names></name><name><surname>Periskova</surname><given-names>I</given-names></name><name><surname>Prlic</surname><given-names>A</given-names></name><name><surname>Randle</surname><given-names>C</given-names></name><name><surname>Rose</surname><given-names>A</given-names></name><name><surname>Rose</surname><given-names>P</given-names></name><name><surname>Sala</surname><given-names>R</given-names></name><name><surname>Sekharan</surname><given-names>M</given-names></name><name><surname>Shao</surname><given-names>C</given-names></name><name><surname>Tan</surname><given-names>L</given-names></name><name><surname>Tao</surname><given-names>Y-P</given-names></name><name><surname>Valasatava</surname><given-names>Y</given-names></name><name><surname>Voigt</surname><given-names>M</given-names></name><name><surname>Westbrook</surname><given-names>J</given-names></name><name><surname>Woo</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Young</surname><given-names>J</given-names></name><name><surname>Zhuravleva</surname><given-names>M</given-names></name><name><surname>Zardecki</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>RCSB protein data bank: biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D464</fpage><lpage>D474</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1004</pub-id><pub-id pub-id-type="pmid">30357411</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canon</surname><given-names>J</given-names></name><name><surname>Rex</surname><given-names>K</given-names></name><name><surname>Saiki</surname><given-names>AY</given-names></name><name><surname>Mohr</surname><given-names>C</given-names></name><name><surname>Cooke</surname><given-names>K</given-names></name><name><surname>Bagal</surname><given-names>D</given-names></name><name><surname>Gaida</surname><given-names>K</given-names></name><name><surname>Holt</surname><given-names>T</given-names></name><name><surname>Knutson</surname><given-names>CG</given-names></name><name><surname>Koppada</surname><given-names>N</given-names></name><name><surname>Lanman</surname><given-names>BA</given-names></name><name><surname>Werner</surname><given-names>J</given-names></name><name><surname>Rapaport</surname><given-names>AS</given-names></name><name><surname>San Miguel</surname><given-names>T</given-names></name><name><surname>Ortiz</surname><given-names>R</given-names></name><name><surname>Osgood</surname><given-names>T</given-names></name><name><surname>Sun</surname><given-names>J-R</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>McCarter</surname><given-names>JD</given-names></name><name><surname>Volak</surname><given-names>LP</given-names></name><name><surname>Houk</surname><given-names>BE</given-names></name><name><surname>Fakih</surname><given-names>MG</given-names></name><name><surname>O’Neil</surname><given-names>BH</given-names></name><name><surname>Price</surname><given-names>TJ</given-names></name><name><surname>Falchook</surname><given-names>GS</given-names></name><name><surname>Desai</surname><given-names>J</given-names></name><name><surname>Kuo</surname><given-names>J</given-names></name><name><surname>Govindan</surname><given-names>R</given-names></name><name><surname>Hong</surname><given-names>DS</given-names></name><name><surname>Ouyang</surname><given-names>W</given-names></name><name><surname>Henary</surname><given-names>H</given-names></name><name><surname>Arvedson</surname><given-names>T</given-names></name><name><surname>Cee</surname><given-names>VJ</given-names></name><name><surname>Lipford</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity</article-title><source>Nature</source><volume>575</volume><fpage>217</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1694-1</pub-id><pub-id pub-id-type="pmid">31666701</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Gilson</surname><given-names>MK</given-names></name></person-group><year iso-8601-date="2001">2001a</year><article-title>The binding database: overview and user’s guide</article-title><source>Biopolymers</source><volume>61</volume><fpage>127</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1002/1097-0282(2002)61:2&lt;127::AID-BIP10076&gt;3.0.CO;2-N</pub-id><pub-id pub-id-type="pmid">11987162</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Gilson</surname><given-names>MK</given-names></name></person-group><year iso-8601-date="2001">2001b</year><article-title>BindingDB: a web-accessible molecular recognition database</article-title><source>Combinatorial Chemistry &amp; High Throughput Screening</source><volume>4</volume><fpage>719</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.2174/1386207013330670</pub-id><pub-id pub-id-type="pmid">11812264</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Gilson</surname><given-names>MK</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The binding database: data management and interface design</article-title><source>Bioinformatics</source><volume>18</volume><fpage>130</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/18.1.130</pub-id><pub-id pub-id-type="pmid">11836221</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherfils</surname><given-names>J</given-names></name><name><surname>Zeghouf</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Regulation of small GTPases by GEFs, gaps, and GDIs</article-title><source>Physiological Reviews</source><volume>93</volume><fpage>269</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1152/physrev.00003.2012</pub-id><pub-id pub-id-type="pmid">23303910</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>AD</given-names></name><name><surname>Fesik</surname><given-names>SW</given-names></name><name><surname>Kimmelman</surname><given-names>AC</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Der</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Drugging the undruggable Ras: mission possible?</article-title><source>Nature Reviews Drug Discovery</source><volume>13</volume><fpage>828</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1038/nrd4389</pub-id><pub-id pub-id-type="pmid">25323927</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darden</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Particle mesh ewald: an n log (n) method for ewald sums in large systems</article-title><source>J Chem Phys</source><volume>98</volume><fpage>10089</fpage><lpage>10092</lpage></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Luca</surname><given-names>A</given-names></name><name><surname>Maiello</surname><given-names>MR</given-names></name><name><surname>D’Alessio</surname><given-names>A</given-names></name><name><surname>Pergameno</surname><given-names>M</given-names></name><name><surname>Normanno</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The ras/raf/mek/erk and the pi3k/akt signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches</article-title><source>Expert Opinion on Therapeutic Targets</source><volume>16 Suppl 2</volume><fpage>S17</fpage><lpage>S27</lpage><pub-id pub-id-type="doi">10.1517/14728222.2011.639361</pub-id><pub-id pub-id-type="pmid">22443084</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Downward</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>The Ras superfamily of small GTP-binding proteins</article-title><source>Trends in Biochemical Sciences</source><volume>15</volume><fpage>469</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1016/0968-0004(90)90300-Z</pub-id><pub-id pub-id-type="pmid">2127644</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drugan</surname><given-names>JK</given-names></name><name><surname>Khosravi-Far</surname><given-names>R</given-names></name><name><surname>White</surname><given-names>MA</given-names></name><name><surname>Der</surname><given-names>CJ</given-names></name><name><surname>Sung</surname><given-names>Y-J</given-names></name><name><surname>Hwang</surname><given-names>Y-W</given-names></name><name><surname>Campbell</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Ras interaction with two distinct binding domains in Raf-1 5 be required for Ras transformation</article-title><source>Journal of Biological Chemistry</source><volume>271</volume><fpage>233</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.1.233</pub-id><pub-id pub-id-type="pmid">8550565</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duffy</surname><given-names>MJ</given-names></name><name><surname>Crown</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Drugging “undruggable” genes for cancer treatment: are we making progress?</article-title><source>International Journal of Cancer</source><volume>148</volume><fpage>8</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1002/ijc.33197</pub-id><pub-id pub-id-type="pmid">32638380</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eser</surname><given-names>S</given-names></name><name><surname>Schnieke</surname><given-names>A</given-names></name><name><surname>Schneider</surname><given-names>G</given-names></name><name><surname>Saur</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Oncogenic KRAS signalling in pancreatic cancer</article-title><source>British Journal of Cancer</source><volume>111</volume><fpage>817</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.1038/bjc.2014.215</pub-id><pub-id pub-id-type="pmid">24755884</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Essmann</surname><given-names>U</given-names></name><name><surname>Perera</surname><given-names>L</given-names></name><name><surname>Berkowitz</surname><given-names>ML</given-names></name><name><surname>Darden</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Pedersen</surname><given-names>LG</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>A smooth particle mesh ewald method</article-title><source>J Chem Phys</source><volume>103</volume><fpage>8577</fpage><lpage>8593</lpage><pub-id pub-id-type="doi">10.1063/1.470117</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferro</surname><given-names>E</given-names></name><name><surname>Trabalzini</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Ralgds family members couple Ras to Ral signalling and that’s not all</article-title><source>Cellular Signalling</source><volume>22</volume><fpage>1804</fpage><lpage>1810</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2010.05.010</pub-id><pub-id pub-id-type="pmid">20478380</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fetics</surname><given-names>SK</given-names></name><name><surname>Guterres</surname><given-names>H</given-names></name><name><surname>Kearney</surname><given-names>BM</given-names></name><name><surname>Buhrman</surname><given-names>G</given-names></name><name><surname>Ma</surname><given-names>B</given-names></name><name><surname>Nussinov</surname><given-names>R</given-names></name><name><surname>Mattos</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Allosteric effects of the oncogenic rasq61l mutant on raf-RBD</article-title><source>Structure</source><volume>23</volume><fpage>505</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1016/j.str.2014.12.017</pub-id><pub-id pub-id-type="pmid">25684575</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geyer</surname><given-names>M</given-names></name><name><surname>Wittinghofer</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Gefs, gaps, GDIs and effectors: taking a closer (3D) look at the regulation of Ras-related GTP-binding proteins</article-title><source>Current Opinion in Structural Biology</source><volume>7</volume><fpage>786</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1016/s0959-440x(97)80147-9</pub-id><pub-id pub-id-type="pmid">9434896</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilson</surname><given-names>MK</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Baitaluk</surname><given-names>M</given-names></name><name><surname>Nicola</surname><given-names>G</given-names></name><name><surname>Hwang</surname><given-names>L</given-names></name><name><surname>Chong</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>BindingDB in 2015: a public database for medicinal chemistry, computational chemistry and systems pharmacology</article-title><source>Nucleic Acids Research</source><volume>44</volume><fpage>D1045</fpage><lpage>D1053</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv1072</pub-id><pub-id pub-id-type="pmid">26481362</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grand</surname><given-names>RJ</given-names></name><name><surname>Owen</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>The biochemistry of ras p21</article-title><source>The Biochemical Journal</source><volume>279 (Pt 3)</volume><fpage>609</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1042/bj2790609</pub-id><pub-id pub-id-type="pmid">1953656</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gysin</surname><given-names>S</given-names></name><name><surname>Salt</surname><given-names>M</given-names></name><name><surname>Young</surname><given-names>A</given-names></name><name><surname>McCormick</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Therapeutic strategies for targeting Ras proteins</article-title><source>Genes &amp; Cancer</source><volume>2</volume><fpage>359</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1177/1947601911412376</pub-id><pub-id pub-id-type="pmid">21779505</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hah</surname><given-names>JH</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Pickering</surname><given-names>CR</given-names></name><name><surname>Frederick</surname><given-names>MJ</given-names></name><name><surname>Andrews</surname><given-names>GA</given-names></name><name><surname>Jasser</surname><given-names>SA</given-names></name><name><surname>Fooshee</surname><given-names>DR</given-names></name><name><surname>Milas</surname><given-names>ZL</given-names></name><name><surname>Galer</surname><given-names>C</given-names></name><name><surname>Sano</surname><given-names>D</given-names></name><name><surname>William</surname><given-names>WN</given-names><suffix>Jr</suffix></name><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Heymach</surname><given-names>J</given-names></name><name><surname>Byers</surname><given-names>LA</given-names></name><name><surname>Papadimitrakopoulou</surname><given-names>V</given-names></name><name><surname>Myers</surname><given-names>JN</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Hras mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells</article-title><source>Head &amp; Neck</source><volume>36</volume><fpage>1547</fpage><lpage>1554</lpage><pub-id pub-id-type="doi">10.1002/hed.23499</pub-id><pub-id pub-id-type="pmid">24123531</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halgren</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>New method for fast and accurate binding-site identification and analysis</article-title><source>Chemical Biology &amp; Drug Design</source><volume>69</volume><fpage>146</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1111/j.1747-0285.2007.00483.x</pub-id><pub-id pub-id-type="pmid">17381729</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halgren</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Identifying and characterizing binding sites and assessing druggability</article-title><source>Journal of Chemical Information and Modeling</source><volume>49</volume><fpage>377</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1021/ci800324m</pub-id><pub-id pub-id-type="pmid">19434839</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holderfield</surname><given-names>M</given-names></name><name><surname>Deuker</surname><given-names>MM</given-names></name><name><surname>McCormick</surname><given-names>F</given-names></name><name><surname>McMahon</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Targeting Raf kinases for cancer therapy: BRAF-mutated melanoma and beyond</article-title><source>Nature Reviews. Cancer</source><volume>14</volume><fpage>455</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1038/nrc3760</pub-id><pub-id pub-id-type="pmid">24957944</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Southall</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yasgar</surname><given-names>A</given-names></name><name><surname>Shinn</surname><given-names>P</given-names></name><name><surname>Jadhav</surname><given-names>A</given-names></name><name><surname>Nguyen</surname><given-names>D-T</given-names></name><name><surname>Austin</surname><given-names>CP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The ncgc pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics</article-title><source>Science Translational Medicine</source><volume>3</volume><elocation-id>80</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3001862</pub-id><pub-id pub-id-type="pmid">21525397</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humphrey</surname><given-names>W</given-names></name><name><surname>Dalke</surname><given-names>A</given-names></name><name><surname>Schulten</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>VMD: visual molecular dynamics</article-title><source>Journal of Molecular Graphics</source><volume>14</volume><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/0263-7855(96)00018-5</pub-id><pub-id pub-id-type="pmid">8744570</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Matplotlib: a 2D graphics environment</article-title><source>Computing in Science &amp; Engineering</source><volume>9</volume><fpage>90</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1109/MCSE.2007.55</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ilter</surname><given-names>M</given-names></name><name><surname>Sensoy</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Catalytically competent non-transforming h-ras<sup>g12p</sup> mutant provides insight into molecular switch function and gap-independent gtpase activity of ras</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>10967</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-47481-1</pub-id><pub-id pub-id-type="pmid">31358828</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jalalypour</surname><given-names>F</given-names></name><name><surname>Sensoy</surname><given-names>O</given-names></name><name><surname>Atilgan</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Perturb-scan-pull: a novel method facilitating conformational transitions in proteins</article-title><source>Journal of Chemical Theory and Computation</source><volume>16</volume><fpage>3825</fpage><lpage>3841</lpage><pub-id pub-id-type="doi">10.1021/acs.jctc.9b01222</pub-id><pub-id pub-id-type="pmid">32324386</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Iyer</surname><given-names>VG</given-names></name><name><surname>Im</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>CHARMM-gui: a web-based graphical user interface for charmm</article-title><source>Journal of Computational Chemistry</source><volume>29</volume><fpage>1859</fpage><lpage>1865</lpage><pub-id pub-id-type="doi">10.1002/jcc.20945</pub-id><pub-id pub-id-type="pmid">18351591</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>LN</given-names></name><name><surname>Lewis</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Structural basis for control by phosphorylation</article-title><source>Chemical Reviews</source><volume>101</volume><fpage>2209</fpage><lpage>2242</lpage><pub-id pub-id-type="doi">10.1021/cr000225s</pub-id><pub-id pub-id-type="pmid">11749371</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>CW</given-names></name><name><surname>Mattos</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The allosteric switch and conformational states in Ras GTPase affected by small molecules</article-title><source>The Enzymes</source><volume>33 Pt A</volume><fpage>41</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-416749-0.00003-8</pub-id><pub-id pub-id-type="pmid">25033800</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>CW</given-names></name><name><surname>Reid</surname><given-names>D</given-names></name><name><surname>Parker</surname><given-names>JA</given-names></name><name><surname>Salter</surname><given-names>S</given-names></name><name><surname>Knihtila</surname><given-names>R</given-names></name><name><surname>Kuzmic</surname><given-names>P</given-names></name><name><surname>Mattos</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The small GTPases K-Ras, N-ras, and H-Ras have distinct biochemical properties determined by allosteric effects</article-title><source>The Journal of Biological Chemistry</source><volume>292</volume><fpage>12981</fpage><lpage>12993</lpage><pub-id pub-id-type="doi">10.1074/jbc.M117.778886</pub-id><pub-id pub-id-type="pmid">28630043</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kano</surname><given-names>Y</given-names></name><name><surname>Gebregiworgis</surname><given-names>T</given-names></name><name><surname>Marshall</surname><given-names>CB</given-names></name><name><surname>Radulovich</surname><given-names>N</given-names></name><name><surname>Poon</surname><given-names>BPK</given-names></name><name><surname>St-Germain</surname><given-names>J</given-names></name><name><surname>Cook</surname><given-names>JD</given-names></name><name><surname>Valencia-Sama</surname><given-names>I</given-names></name><name><surname>Grant</surname><given-names>BMM</given-names></name><name><surname>Herrera</surname><given-names>SG</given-names></name><name><surname>Miao</surname><given-names>J</given-names></name><name><surname>Raught</surname><given-names>B</given-names></name><name><surname>Irwin</surname><given-names>MS</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Yeh</surname><given-names>JJ</given-names></name><name><surname>Zhang</surname><given-names>Z-Y</given-names></name><name><surname>Tsao</surname><given-names>M-S</given-names></name><name><surname>Ikura</surname><given-names>M</given-names></name><name><surname>Ohh</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Tyrosyl phosphorylation of kras stalls gtpase cycle via alteration of switch i and ii conformation</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>224</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-08115-8</pub-id><pub-id pub-id-type="pmid">30644389</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>AQ</given-names></name><name><surname>Kuttikrishnan</surname><given-names>S</given-names></name><name><surname>Siveen</surname><given-names>KS</given-names></name><name><surname>Prabhu</surname><given-names>KS</given-names></name><name><surname>Shanmugakonar</surname><given-names>M</given-names></name><name><surname>Al-Naemi</surname><given-names>HA</given-names></name><name><surname>Haris</surname><given-names>M</given-names></name><name><surname>Dermime</surname><given-names>S</given-names></name><name><surname>Uddin</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>RAS-mediated oncogenic signaling pathways in human malignancies</article-title><source>Seminars in Cancer Biology</source><volume>54</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2018.03.001</pub-id><pub-id pub-id-type="pmid">29524560</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>I</given-names></name><name><surname>Rhett</surname><given-names>JM</given-names></name><name><surname>O’Bryan</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Therapeutic targeting of ras: new hope for drugging the “undruggable.”</article-title><source>Biochimica et Biophysica Acta. Molecular Cell Research</source><volume>1867</volume><elocation-id>118570</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbamcr.2019.118570</pub-id><pub-id pub-id-type="pmid">31678118</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>I</given-names></name><name><surname>Marelia-Bennet</surname><given-names>C</given-names></name><name><surname>Lefler</surname><given-names>J</given-names></name><name><surname>Zuberi</surname><given-names>M</given-names></name><name><surname>Denbaum</surname><given-names>E</given-names></name><name><surname>Koide</surname><given-names>A</given-names></name><name><surname>Connor</surname><given-names>DM</given-names></name><name><surname>Broome</surname><given-names>A-M</given-names></name><name><surname>Pécot</surname><given-names>T</given-names></name><name><surname>Timmers</surname><given-names>C</given-names></name><name><surname>Ostrowski</surname><given-names>MC</given-names></name><name><surname>Koide</surname><given-names>S</given-names></name><name><surname>O’Bryan</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Targeting the kras α4-α5 allosteric interface inhibits pancreatic cancer tumorigenesis</article-title><source>Small GTPases</source><volume>13</volume><fpage>114</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1080/21541248.2021.1906621</pub-id><pub-id pub-id-type="pmid">33949915</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Jo</surname><given-names>S</given-names></name><name><surname>Brooks</surname><given-names>CL</given-names></name><name><surname>Lee</surname><given-names>HS</given-names></name><name><surname>Im</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CHARMM-gui ligand reader and modeler for CHARMM force field generation of small molecules</article-title><source>Journal of Computational Chemistry</source><volume>38</volume><fpage>1879</fpage><lpage>1886</lpage><pub-id pub-id-type="doi">10.1002/jcc.24829</pub-id><pub-id pub-id-type="pmid">28497616</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knight</surname><given-names>T</given-names></name><name><surname>Irving</surname><given-names>JAE</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Ras/raf/mek/erk pathway activation in childhood acute lymphoblastic leukemia and its therapeutic targeting</article-title><source>Frontiers in Oncology</source><volume>4</volume><elocation-id>160</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2014.00160</pub-id><pub-id pub-id-type="pmid">25009801</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knox</surname><given-names>C</given-names></name><name><surname>Law</surname><given-names>V</given-names></name><name><surname>Jewison</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Ly</surname><given-names>S</given-names></name><name><surname>Frolkis</surname><given-names>A</given-names></name><name><surname>Pon</surname><given-names>A</given-names></name><name><surname>Banco</surname><given-names>K</given-names></name><name><surname>Mak</surname><given-names>C</given-names></name><name><surname>Neveu</surname><given-names>V</given-names></name><name><surname>Djoumbou</surname><given-names>Y</given-names></name><name><surname>Eisner</surname><given-names>R</given-names></name><name><surname>Guo</surname><given-names>AC</given-names></name><name><surname>Wishart</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>DrugBank 3.0: a comprehensive resource for “omics” research on drugs</article-title><source>Nucleic Acids Research</source><volume>39</volume><fpage>D1035</fpage><lpage>D1041</lpage><pub-id pub-id-type="doi">10.1093/nar/gkq1126</pub-id><pub-id pub-id-type="pmid">21059682</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krens</surname><given-names>LL</given-names></name><name><surname>Baas</surname><given-names>JM</given-names></name><name><surname>Gelderblom</surname><given-names>H</given-names></name><name><surname>Guchelaar</surname><given-names>H-J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Therapeutic modulation of K-Ras signaling in colorectal cancer</article-title><source>Drug Discovery Today</source><volume>15</volume><fpage>502</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2010.05.012</pub-id><pub-id pub-id-type="pmid">20594936</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamontanara</surname><given-names>AJ</given-names></name><name><surname>Georgeon</surname><given-names>S</given-names></name><name><surname>Tria</surname><given-names>G</given-names></name><name><surname>Svergun</surname><given-names>DI</given-names></name><name><surname>Hantschel</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The sh2 domain of abl kinases regulates kinase autophosphorylation by controlling activation loop accessibility</article-title><source>Nature Communications</source><volume>5</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1038/ncomms6470</pub-id><pub-id pub-id-type="pmid">25399951</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Law</surname><given-names>V</given-names></name><name><surname>Knox</surname><given-names>C</given-names></name><name><surname>Djoumbou</surname><given-names>Y</given-names></name><name><surname>Jewison</surname><given-names>T</given-names></name><name><surname>Guo</surname><given-names>AC</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Maciejewski</surname><given-names>A</given-names></name><name><surname>Arndt</surname><given-names>D</given-names></name><name><surname>Wilson</surname><given-names>M</given-names></name><name><surname>Neveu</surname><given-names>V</given-names></name><name><surname>Tang</surname><given-names>A</given-names></name><name><surname>Gabriel</surname><given-names>G</given-names></name><name><surname>Ly</surname><given-names>C</given-names></name><name><surname>Adamjee</surname><given-names>S</given-names></name><name><surname>Dame</surname><given-names>ZT</given-names></name><name><surname>Han</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Wishart</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>DrugBank 4.0: shedding new light on drug metabolism</article-title><source>Nucleic Acids Research</source><volume>42</volume><fpage>D1091</fpage><lpage>D1097</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt1068</pub-id><pub-id pub-id-type="pmid">24203711</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ledford</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cancer: the ras renaissance</article-title><source>Nature</source><volume>520</volume><fpage>278</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1038/520278a</pub-id><pub-id pub-id-type="pmid">25877186</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Lindahl</surname><given-names>A</given-names></name><name><surname>van der Spoel</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>GROMACS 2021</data-title><source>Zenodo</source><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.4457591">https://doi.org/10.5281/zenodo.4457591</ext-link></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Wen</surname><given-names>X</given-names></name><name><surname>Jorissen</surname><given-names>RN</given-names></name><name><surname>Gilson</surname><given-names>MK</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities</article-title><source>Nucleic Acids Research</source><volume>35</volume><fpage>D198</fpage><lpage>D201</lpage><pub-id pub-id-type="doi">10.1093/nar/gkl999</pub-id><pub-id pub-id-type="pmid">17145705</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loving</surname><given-names>K</given-names></name><name><surname>Salam</surname><given-names>NK</given-names></name><name><surname>Sherman</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation</article-title><source>Journal of Computer-Aided Molecular Design</source><volume>23</volume><fpage>541</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1007/s10822-009-9268-1</pub-id><pub-id pub-id-type="pmid">19421721</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowy</surname><given-names>DR</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>DeClue</surname><given-names>JE</given-names></name><name><surname>Willumsen</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Regulation of p21ras activity</article-title><source>Trends in Genetics</source><volume>7</volume><fpage>346</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1016/0168-9525(91)90253-m</pub-id><pub-id pub-id-type="pmid">1820685</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Jang</surname><given-names>H</given-names></name><name><surname>Muratcioglu</surname><given-names>S</given-names></name><name><surname>Gursoy</surname><given-names>A</given-names></name><name><surname>Keskin</surname><given-names>O</given-names></name><name><surname>Nussinov</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016a</year><article-title>Ras conformational ensembles, allostery, and signaling</article-title><source>Chemical Reviews</source><volume>116</volume><fpage>6607</fpage><lpage>6665</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.5b00542</pub-id><pub-id pub-id-type="pmid">26815308</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Jang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Nussinov</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016b</year><article-title>Inhibitors of ras-sos interactions</article-title><source>ChemMedChem</source><volume>11</volume><fpage>814</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1002/cmdc.201500481</pub-id><pub-id pub-id-type="pmid">26630662</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malumbres</surname><given-names>M</given-names></name><name><surname>Barbacid</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Ras oncogenes: the first 30 years</article-title><source>Nature Reviews. Cancer</source><volume>3</volume><fpage>459</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1038/nrc1097</pub-id><pub-id pub-id-type="pmid">12778136</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mark</surname><given-names>P</given-names></name><name><surname>Nilsson</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Structure and dynamics of the tip3p, SPC, and spc/e water models at 298 K</article-title><source>The Journal of Physical Chemistry A</source><volume>105</volume><fpage>9954</fpage><lpage>9960</lpage><pub-id pub-id-type="doi">10.1021/jp003020w</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>MJ</given-names></name><name><surname>Pagba</surname><given-names>CV</given-names></name><name><surname>Prakash</surname><given-names>P</given-names></name><name><surname>Naji</surname><given-names>AK</given-names></name><name><surname>van der Hoeven</surname><given-names>D</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Gupta</surname><given-names>AK</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Cho</surname><given-names>K-J</given-names></name><name><surname>Hancock</surname><given-names>JF</given-names></name><name><surname>Gorfe</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Discovery of high-affinity noncovalent allosteric KRAS inhibitors that disrupt effector binding</article-title><source>ACS Omega</source><volume>4</volume><fpage>2921</fpage><lpage>2930</lpage><pub-id pub-id-type="doi">10.1021/acsomega.8b03308</pub-id><pub-id pub-id-type="pmid">30842983</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCormick</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015a</year><article-title>Kras as a therapeutic target</article-title><source>Clinical Cancer Research</source><volume>21</volume><fpage>1797</fpage><lpage>1801</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-2662</pub-id><pub-id pub-id-type="pmid">25878360</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCormick</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015b</year><article-title>The potential of targeting ras proteins in lung cancer</article-title><source>Expert Opinion on Therapeutic Targets</source><volume>19</volume><fpage>451</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1517/14728222.2014.1000304</pub-id><pub-id pub-id-type="pmid">25558943</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="software"><person-group person-group-type="author"><collab>MIDST lab</collab></person-group><year iso-8601-date="2022">2022</year><data-title>PMF_from_SMD_data</data-title><version designator="swh:1:rev:f72f6cbe253ddc4515b47f670eb936a50adc7824">swh:1:rev:f72f6cbe253ddc4515b47f670eb936a50adc7824</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:76cffa3df2bfd8edae4a92604cb0df1187398d6b;origin=https://github.com/midstlab/PMF_from_SMD_data;visit=swh:1:snp:172d53637b2f0b6ada90eeeea7dd46b59c59a824;anchor=swh:1:rev:f72f6cbe253ddc4515b47f670eb936a50adc7824">https://archive.softwareheritage.org/swh:1:dir:76cffa3df2bfd8edae4a92604cb0df1187398d6b;origin=https://github.com/midstlab/PMF_from_SMD_data;visit=swh:1:snp:172d53637b2f0b6ada90eeeea7dd46b59c59a824;anchor=swh:1:rev:f72f6cbe253ddc4515b47f670eb936a50adc7824</ext-link></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milroy</surname><given-names>L-G</given-names></name><name><surname>Ottmann</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The renaissance of Ras</article-title><source>ACS Chemical Biology</source><volume>9</volume><fpage>2447</fpage><lpage>2458</lpage><pub-id pub-id-type="doi">10.1021/cb500555h</pub-id><pub-id pub-id-type="pmid">25148694</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>AR</given-names></name><name><surname>Rosenberg</surname><given-names>SC</given-names></name><name><surname>McCormick</surname><given-names>F</given-names></name><name><surname>Malek</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>RAS-targeted therapies: is the undruggable drugged?</article-title><source>Nature Reviews. Drug Discovery</source><volume>19</volume><fpage>533</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1038/s41573-020-0068-6</pub-id><pub-id pub-id-type="pmid">32528145</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muñoz-Maldonado</surname><given-names>C</given-names></name><name><surname>Zimmer</surname><given-names>Y</given-names></name><name><surname>Medová</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A comparative analysis of individual Ras mutations in cancer biology</article-title><source>Frontiers in Oncology</source><volume>9</volume><elocation-id>1088</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2019.01088</pub-id><pub-id pub-id-type="pmid">31681616</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myers</surname><given-names>MB</given-names></name><name><surname>Banda</surname><given-names>M</given-names></name><name><surname>McKim</surname><given-names>KL</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Powell</surname><given-names>MJ</given-names></name><name><surname>Parsons</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Breast cancer heterogeneity examined by high-sensitivity quantification of PIK3CA, KRAS, HRAS, and BRAF mutations in normal breast and ductal carcinomas</article-title><source>Neoplasia</source><volume>18</volume><fpage>253</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1016/j.neo.2016.03.002</pub-id><pub-id pub-id-type="pmid">27108388</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Bryan</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Pharmacological targeting of ras: recent success with direct inhibitors</article-title><source>Pharmacological Research</source><volume>139</volume><fpage>503</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2018.10.021</pub-id><pub-id pub-id-type="pmid">30366101</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olsson</surname><given-names>MHM</given-names></name><name><surname>Søndergaard</surname><given-names>CR</given-names></name><name><surname>Rostkowski</surname><given-names>M</given-names></name><name><surname>Jensen</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>PROPKA3: consistent treatment of internal and surface residues in empirical pka predictions</article-title><source>Journal of Chemical Theory and Computation</source><volume>7</volume><fpage>525</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1021/ct100578z</pub-id><pub-id pub-id-type="pmid">26596171</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ooi</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>A</given-names></name><name><surname>Esau</surname><given-names>L</given-names></name><name><surname>Lemtiri-Chlieh</surname><given-names>F</given-names></name><name><surname>Gehring</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A guide to transient expression of membrane proteins in hek-293 cells for functional characterization</article-title><source>Frontiers in Physiology</source><volume>7</volume><elocation-id>300</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2016.00300</pub-id><pub-id pub-id-type="pmid">27486406</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostrem</surname><given-names>JM</given-names></name><name><surname>Peters</surname><given-names>U</given-names></name><name><surname>Sos</surname><given-names>ML</given-names></name><name><surname>Wells</surname><given-names>JA</given-names></name><name><surname>Shokat</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions</article-title><source>Nature</source><volume>503</volume><fpage>548</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1038/nature12796</pub-id><pub-id pub-id-type="pmid">24256730</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pai</surname><given-names>EF</given-names></name><name><surname>Krengel</surname><given-names>U</given-names></name><name><surname>Petsko</surname><given-names>GA</given-names></name><name><surname>Goody</surname><given-names>RS</given-names></name><name><surname>Kabsch</surname><given-names>W</given-names></name><name><surname>Wittinghofer</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Refined crystal structure of the triphosphate conformation of H-ras p21 at 1.35 A resolution: implications for the mechanism of GTP hydrolysis</article-title><source>The EMBO Journal</source><volume>9</volume><fpage>2351</fpage><lpage>2359</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1990.tb07409.x</pub-id><pub-id pub-id-type="pmid">2196171</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrone</surname><given-names>P</given-names></name><name><surname>Pande</surname><given-names>VS</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Can conformational change be described by only a few normal modes?</article-title><source>Biophysical Journal</source><volume>90</volume><fpage>1583</fpage><lpage>1593</lpage><pub-id pub-id-type="doi">10.1529/biophysj.105.070045</pub-id><pub-id pub-id-type="pmid">16361336</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prior</surname><given-names>IA</given-names></name><name><surname>Lewis</surname><given-names>PD</given-names></name><name><surname>Mattos</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A comprehensive survey of Ras mutations in cancer</article-title><source>Cancer Research</source><volume>72</volume><fpage>2457</fpage><lpage>2467</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-2612</pub-id><pub-id pub-id-type="pmid">22589270</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prior</surname><given-names>IA</given-names></name><name><surname>Hood</surname><given-names>FE</given-names></name><name><surname>Hartley</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The frequency of Ras mutations in cancer</article-title><source>Cancer Research</source><volume>80</volume><fpage>2969</fpage><lpage>2974</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-19-3682</pub-id><pub-id pub-id-type="pmid">32209560</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Release</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><source>4: Glide</source><publisher-loc>New York, USA</publisher-loc><publisher-name>Schrodinger</publisher-name></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roos</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Damm</surname><given-names>W</given-names></name><name><surname>Reboul</surname><given-names>M</given-names></name><name><surname>Stevenson</surname><given-names>JM</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Dahlgren</surname><given-names>MK</given-names></name><name><surname>Mondal</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Abel</surname><given-names>R</given-names></name><name><surname>Friesner</surname><given-names>RA</given-names></name><name><surname>Harder</surname><given-names>ED</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>OPLS3e: extending force field coverage for drug-like small molecules</article-title><source>Journal of Chemical Theory and Computation</source><volume>15</volume><fpage>1863</fpage><lpage>1874</lpage><pub-id pub-id-type="doi">10.1021/acs.jctc.8b01026</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruess</surname><given-names>DA</given-names></name><name><surname>Heynen</surname><given-names>GJ</given-names></name><name><surname>Ciecielski</surname><given-names>KJ</given-names></name><name><surname>Ai</surname><given-names>J</given-names></name><name><surname>Berninger</surname><given-names>A</given-names></name><name><surname>Kabacaoglu</surname><given-names>D</given-names></name><name><surname>Görgülü</surname><given-names>K</given-names></name><name><surname>Dantes</surname><given-names>Z</given-names></name><name><surname>Wörmann</surname><given-names>SM</given-names></name><name><surname>Diakopoulos</surname><given-names>KN</given-names></name><name><surname>Karpathaki</surname><given-names>AF</given-names></name><name><surname>Kowalska</surname><given-names>M</given-names></name><name><surname>Kaya-Aksoy</surname><given-names>E</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>van der Laan</surname><given-names>EAZ</given-names></name><name><surname>López-Alberca</surname><given-names>MP</given-names></name><name><surname>Nazaré</surname><given-names>M</given-names></name><name><surname>Reichert</surname><given-names>M</given-names></name><name><surname>Saur</surname><given-names>D</given-names></name><name><surname>Erkan</surname><given-names>MM</given-names></name><name><surname>Hopt</surname><given-names>UT</given-names></name><name><surname>Sainz</surname><given-names>B</given-names><suffix>Jr</suffix></name><name><surname>Birchmeier</surname><given-names>W</given-names></name><name><surname>Schmid</surname><given-names>RM</given-names></name><name><surname>Lesina</surname><given-names>M</given-names></name><name><surname>Algül</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mutant KRas-driven cancers depend on ptpn11/shp2 phosphatase</article-title><source>Nature Medicine</source><volume>24</volume><fpage>954</fpage><lpage>960</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0024-8</pub-id><pub-id pub-id-type="pmid">29808009</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salam</surname><given-names>NK</given-names></name><name><surname>Nuti</surname><given-names>R</given-names></name><name><surname>Sherman</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Novel method for generating structure-based pharmacophores using energetic analysis</article-title><source>Journal of Chemical Information and Modeling</source><volume>49</volume><fpage>2356</fpage><lpage>2368</lpage><pub-id pub-id-type="doi">10.1021/ci900212v</pub-id><pub-id pub-id-type="pmid">19761201</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sastry</surname><given-names>GM</given-names></name><name><surname>Adzhigirey</surname><given-names>M</given-names></name><name><surname>Day</surname><given-names>T</given-names></name><name><surname>Annabhimoju</surname><given-names>R</given-names></name><name><surname>Sherman</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments</article-title><source>Journal of Computer-Aided Molecular Design</source><volume>27</volume><fpage>221</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1007/s10822-013-9644-8</pub-id><pub-id pub-id-type="pmid">23579614</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shima</surname><given-names>F</given-names></name><name><surname>Ijiri</surname><given-names>Y</given-names></name><name><surname>Muraoka</surname><given-names>S</given-names></name><name><surname>Liao</surname><given-names>J</given-names></name><name><surname>Ye</surname><given-names>M</given-names></name><name><surname>Araki</surname><given-names>M</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>N</given-names></name><name><surname>Sugimoto</surname><given-names>T</given-names></name><name><surname>Yoshikawa</surname><given-names>Y</given-names></name><name><surname>Kumasaka</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Tamura</surname><given-names>A</given-names></name><name><surname>Kataoka</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Structural basis for conformational dynamics of GTP-bound Ras protein</article-title><source>The Journal of Biological Chemistry</source><volume>285</volume><fpage>22696</fpage><lpage>22705</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.125161</pub-id><pub-id pub-id-type="pmid">20479006</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simanshu</surname><given-names>DK</given-names></name><name><surname>Nissley</surname><given-names>DV</given-names></name><name><surname>McCormick</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Ras proteins and their regulators in human disease</article-title><source>Cell</source><volume>170</volume><fpage>17</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.06.009</pub-id><pub-id pub-id-type="pmid">28666118</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Søndergaard</surname><given-names>CR</given-names></name><name><surname>Olsson</surname><given-names>MHM</given-names></name><name><surname>Rostkowski</surname><given-names>M</given-names></name><name><surname>Jensen</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Improved treatment of ligands and coupling effects in empirical calculation and rationalization of pKa values</article-title><source>Journal of Chemical Theory and Computation</source><volume>7</volume><fpage>2284</fpage><lpage>2295</lpage><pub-id pub-id-type="doi">10.1021/ct200133y</pub-id><pub-id pub-id-type="pmid">26606496</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soteras Gutiérrez</surname><given-names>I</given-names></name><name><surname>Lin</surname><given-names>F-Y</given-names></name><name><surname>Vanommeslaeghe</surname><given-names>K</given-names></name><name><surname>Lemkul</surname><given-names>JA</given-names></name><name><surname>Armacost</surname><given-names>KA</given-names></name><name><surname>Brooks</surname><given-names>CL</given-names></name><name><surname>MacKerell</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Parametrization of halogen bonds in the charmm general force field: improved treatment of ligand-protein interactions</article-title><source>Bioorganic &amp; Medicinal Chemistry</source><volume>24</volume><fpage>4812</fpage><lpage>4825</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2016.06.034</pub-id><pub-id pub-id-type="pmid">27353885</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephen</surname><given-names>AG</given-names></name><name><surname>Esposito</surname><given-names>D</given-names></name><name><surname>Bagni</surname><given-names>RK</given-names></name><name><surname>McCormick</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Dragging Ras back in the ring</article-title><source>Cancer Cell</source><volume>25</volume><fpage>272</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2014.02.017</pub-id><pub-id pub-id-type="pmid">24651010</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1998">1998</year><source>An Efficient Library for Parallel Ray Tracing and Animation</source><publisher-loc>Newyork, USA</publisher-loc><publisher-name>University of Missouri-Rolla</publisher-name></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stuckey</surname><given-names>DW</given-names></name><name><surname>Hingtgen</surname><given-names>SD</given-names></name><name><surname>Karakas</surname><given-names>N</given-names></name><name><surname>Rich</surname><given-names>BE</given-names></name><name><surname>Shah</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Engineering toxin-resistant therapeutic stem cells to treat brain tumors</article-title><source>Stem Cells</source><volume>33</volume><fpage>589</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1002/stem.1874</pub-id><pub-id pub-id-type="pmid">25346520</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takai</surname><given-names>Y</given-names></name><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Matozaki</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Small GTP-binding proteins</article-title><source>Physiological Reviews</source><volume>81</volume><fpage>153</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1152/physrev.2001.81.1.153</pub-id><pub-id pub-id-type="pmid">11152757</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The AACR Project GENIE Consortium</collab><collab>The AACR Project GENIE Consortium</collab><name><surname>André</surname><given-names>F</given-names></name><name><surname>Arnedos</surname><given-names>M</given-names></name><name><surname>Baras</surname><given-names>AS</given-names></name><name><surname>Baselga</surname><given-names>J</given-names></name><name><surname>Bedard</surname><given-names>PL</given-names></name><name><surname>Berger</surname><given-names>MF</given-names></name><name><surname>Bierkens</surname><given-names>M</given-names></name><name><surname>Calvo</surname><given-names>F</given-names></name><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Chakravarty</surname><given-names>D</given-names></name><name><surname>Dang</surname><given-names>KK</given-names></name><name><surname>Davidson</surname><given-names>NE</given-names></name><name><surname>Del Vecchio Fitz</surname><given-names>C</given-names></name><name><surname>Dogan</surname><given-names>S</given-names></name><name><surname>DuBois</surname><given-names>RN</given-names></name><name><surname>Ducar</surname><given-names>MD</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Garcia</surname><given-names>F</given-names></name><name><surname>Gardos</surname><given-names>S</given-names></name><name><surname>Gocke</surname><given-names>CD</given-names></name><name><surname>Gross</surname><given-names>BE</given-names></name><name><surname>Guinney</surname><given-names>J</given-names></name><name><surname>Heins</surname><given-names>ZJ</given-names></name><name><surname>Hintzen</surname><given-names>S</given-names></name><name><surname>Horlings</surname><given-names>H</given-names></name><name><surname>Hudeček</surname><given-names>J</given-names></name><name><surname>Hyman</surname><given-names>DM</given-names></name><name><surname>Kamel-Reid</surname><given-names>S</given-names></name><name><surname>Kandoth</surname><given-names>C</given-names></name><name><surname>Kinyua</surname><given-names>W</given-names></name><name><surname>Kumari</surname><given-names>P</given-names></name><name><surname>Kundra</surname><given-names>R</given-names></name><name><surname>Ladanyi</surname><given-names>M</given-names></name><name><surname>Lefebvre</surname><given-names>C</given-names></name><name><surname>LeNoue-Newton</surname><given-names>ML</given-names></name><name><surname>Lepisto</surname><given-names>EM</given-names></name><name><surname>Levy</surname><given-names>MA</given-names></name><name><surname>Lindeman</surname><given-names>NI</given-names></name><name><surname>Lindsay</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>MacConaill</surname><given-names>LE</given-names></name><name><surname>Maurer</surname><given-names>I</given-names></name><name><surname>Maxwell</surname><given-names>DS</given-names></name><name><surname>Meijer</surname><given-names>GA</given-names></name><name><surname>Meric-Bernstam</surname><given-names>F</given-names></name><name><surname>Micheel</surname><given-names>CM</given-names></name><name><surname>Miller</surname><given-names>C</given-names></name><name><surname>Mills</surname><given-names>G</given-names></name><name><surname>Moore</surname><given-names>ND</given-names></name><name><surname>Nederlof</surname><given-names>PM</given-names></name><name><surname>Omberg</surname><given-names>L</given-names></name><name><surname>Orechia</surname><given-names>JA</given-names></name><name><surname>Park</surname><given-names>BH</given-names></name><name><surname>Pugh</surname><given-names>TJ</given-names></name><name><surname>Reardon</surname><given-names>B</given-names></name><name><surname>Rollins</surname><given-names>BJ</given-names></name><name><surname>Routbort</surname><given-names>MJ</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name><name><surname>Schrag</surname><given-names>D</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Shaw</surname><given-names>KRM</given-names></name><name><surname>Shivdasani</surname><given-names>P</given-names></name><name><surname>Siu</surname><given-names>LL</given-names></name><name><surname>Solit</surname><given-names>DB</given-names></name><name><surname>Sonke</surname><given-names>GS</given-names></name><name><surname>Soria</surname><given-names>JC</given-names></name><name><surname>Sripakdeevong</surname><given-names>P</given-names></name><name><surname>Stickle</surname><given-names>NH</given-names></name><name><surname>Stricker</surname><given-names>TP</given-names></name><name><surname>Sweeney</surname><given-names>SM</given-names></name><name><surname>Taylor</surname><given-names>BS</given-names></name><name><surname>ten Hoeve</surname><given-names>JJ</given-names></name><name><surname>Thomas</surname><given-names>SB</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Van ’T Veer</surname><given-names>LJ</given-names></name><name><surname>van de Velde</surname><given-names>T</given-names></name><name><surname>van Tinteren</surname><given-names>H</given-names></name><name><surname>Velculescu</surname><given-names>VE</given-names></name><name><surname>Virtanen</surname><given-names>C</given-names></name><name><surname>Voest</surname><given-names>EE</given-names></name><name><surname>Wang</surname><given-names>LL</given-names></name><name><surname>Wathoo</surname><given-names>C</given-names></name><name><surname>Watt</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>TV</given-names></name><name><surname>Yu</surname><given-names>E</given-names></name><name><surname>Zehir</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Aacr project genie: powering precision medicine through an international Consortium</article-title><source>Cancer Discovery</source><volume>7</volume><fpage>818</fpage><lpage>831</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-0151</pub-id><pub-id pub-id-type="pmid">28572459</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Travers</surname><given-names>T</given-names></name><name><surname>López</surname><given-names>CA</given-names></name><name><surname>Van</surname><given-names>QN</given-names></name><name><surname>Neale</surname><given-names>C</given-names></name><name><surname>Tonelli</surname><given-names>M</given-names></name><name><surname>Stephen</surname><given-names>AG</given-names></name><name><surname>Gnanakaran</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Molecular recognition of ras/raf complex at the membrane: role of raf cysteine-rich domain</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>8461</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-26832-4</pub-id><pub-id pub-id-type="pmid">29855542</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ursu</surname><given-names>O</given-names></name><name><surname>Holmes</surname><given-names>J</given-names></name><name><surname>Knockel</surname><given-names>J</given-names></name><name><surname>Bologa</surname><given-names>CG</given-names></name><name><surname>Yang</surname><given-names>JJ</given-names></name><name><surname>Mathias</surname><given-names>SL</given-names></name><name><surname>Nelson</surname><given-names>SJ</given-names></name><name><surname>Oprea</surname><given-names>TI</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>DrugCentral: online drug compendium</article-title><source>Nucleic Acids Research</source><volume>45</volume><fpage>D932</fpage><lpage>D939</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw993</pub-id><pub-id pub-id-type="pmid">27789690</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ursu</surname><given-names>O</given-names></name><name><surname>Holmes</surname><given-names>J</given-names></name><name><surname>Bologa</surname><given-names>CG</given-names></name><name><surname>Yang</surname><given-names>JJ</given-names></name><name><surname>Mathias</surname><given-names>SL</given-names></name><name><surname>Stathias</surname><given-names>V</given-names></name><name><surname>Nguyen</surname><given-names>D-T</given-names></name><name><surname>Schürer</surname><given-names>S</given-names></name><name><surname>Oprea</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>DrugCentral 2018: an update</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D963</fpage><lpage>D970</lpage><pub-id pub-id-type="doi">10.1093/nar/gky963</pub-id><pub-id pub-id-type="pmid">30371892</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanommeslaeghe</surname><given-names>K</given-names></name><name><surname>Hatcher</surname><given-names>E</given-names></name><name><surname>Acharya</surname><given-names>C</given-names></name><name><surname>Kundu</surname><given-names>S</given-names></name><name><surname>Zhong</surname><given-names>S</given-names></name><name><surname>Shim</surname><given-names>J</given-names></name><name><surname>Darian</surname><given-names>E</given-names></name><name><surname>Guvench</surname><given-names>O</given-names></name><name><surname>Lopes</surname><given-names>P</given-names></name><name><surname>Vorobyov</surname><given-names>I</given-names></name><name><surname>Mackerell</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields</article-title><source>Journal of Computational Chemistry</source><volume>31</volume><fpage>671</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1002/jcc.21367</pub-id><pub-id pub-id-type="pmid">19575467</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanommeslaeghe</surname><given-names>K</given-names></name><name><surname>MacKerell</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Automation of the charmm general force field (cgenff) I: bond perception and atom typing</article-title><source>Journal of Chemical Information and Modeling</source><volume>52</volume><fpage>3144</fpage><lpage>3154</lpage><pub-id pub-id-type="doi">10.1021/ci300363c</pub-id><pub-id pub-id-type="pmid">23146088</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanommeslaeghe</surname><given-names>K</given-names></name><name><surname>Raman</surname><given-names>EP</given-names></name><name><surname>MacKerell</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Automation of the charmm general force field (cgenff) II: assignment of bonded parameters and partial atomic charges</article-title><source>Journal of Chemical Information and Modeling</source><volume>52</volume><fpage>3155</fpage><lpage>3168</lpage><pub-id pub-id-type="doi">10.1021/ci3003649</pub-id><pub-id pub-id-type="pmid">23145473</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vetter</surname><given-names>IR</given-names></name><name><surname>Wittinghofer</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The guanine nucleotide-binding switch in three dimensions</article-title><source>Science</source><volume>294</volume><fpage>1299</fpage><lpage>1304</lpage><pub-id pub-id-type="doi">10.1126/science.1062023</pub-id><pub-id pub-id-type="pmid">11701921</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vigil</surname><given-names>D</given-names></name><name><surname>Cherfils</surname><given-names>J</given-names></name><name><surname>Rossman</surname><given-names>KL</given-names></name><name><surname>Der</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Ras superfamily GEFs and gaps: validated and tractable targets for cancer therapy?</article-title><source>Nature Reviews. Cancer</source><volume>10</volume><fpage>842</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1038/nrc2960</pub-id><pub-id pub-id-type="pmid">21102635</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ji</surname><given-names>D</given-names></name><name><surname>Lei</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Ni</surname><given-names>D</given-names></name><name><surname>Pu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mechanistic insights into the effect of phosphorylation on ras conformational dynamics and its interactions with cell signaling proteins</article-title><source>Computational and Structural Biotechnology Journal</source><volume>19</volume><fpage>1184</fpage><lpage>1199</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2021.01.044</pub-id><pub-id pub-id-type="pmid">33680360</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wishart</surname><given-names>DS</given-names></name><name><surname>Knox</surname><given-names>C</given-names></name><name><surname>Guo</surname><given-names>AC</given-names></name><name><surname>Shrivastava</surname><given-names>S</given-names></name><name><surname>Hassanali</surname><given-names>M</given-names></name><name><surname>Stothard</surname><given-names>P</given-names></name><name><surname>Chang</surname><given-names>Z</given-names></name><name><surname>Woolsey</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>DrugBank: a comprehensive resource for in silico drug discovery and exploration</article-title><source>Nucleic Acids Research</source><volume>34</volume><fpage>D668</fpage><lpage>D672</lpage><pub-id pub-id-type="doi">10.1093/nar/gkj067</pub-id><pub-id pub-id-type="pmid">16381955</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wishart</surname><given-names>DS</given-names></name><name><surname>Knox</surname><given-names>C</given-names></name><name><surname>Guo</surname><given-names>AC</given-names></name><name><surname>Cheng</surname><given-names>D</given-names></name><name><surname>Shrivastava</surname><given-names>S</given-names></name><name><surname>Tzur</surname><given-names>D</given-names></name><name><surname>Gautam</surname><given-names>B</given-names></name><name><surname>Hassanali</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>DrugBank: a knowledgebase for drugs, drug actions and drug targets</article-title><source>Nucleic Acids Research</source><volume>36</volume><fpage>D901</fpage><lpage>D906</lpage><pub-id pub-id-type="doi">10.1093/nar/gkm958</pub-id><pub-id pub-id-type="pmid">18048412</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wishart</surname><given-names>DS</given-names></name><name><surname>Feunang</surname><given-names>YD</given-names></name><name><surname>Guo</surname><given-names>AC</given-names></name><name><surname>Lo</surname><given-names>EJ</given-names></name><name><surname>Marcu</surname><given-names>A</given-names></name><name><surname>Grant</surname><given-names>JR</given-names></name><name><surname>Sajed</surname><given-names>T</given-names></name><name><surname>Johnson</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Sayeeda</surname><given-names>Z</given-names></name><name><surname>Assempour</surname><given-names>N</given-names></name><name><surname>Iynkkaran</surname><given-names>I</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Maciejewski</surname><given-names>A</given-names></name><name><surname>Gale</surname><given-names>N</given-names></name><name><surname>Wilson</surname><given-names>A</given-names></name><name><surname>Chin</surname><given-names>L</given-names></name><name><surname>Cummings</surname><given-names>R</given-names></name><name><surname>Le</surname><given-names>D</given-names></name><name><surname>Pon</surname><given-names>A</given-names></name><name><surname>Knox</surname><given-names>C</given-names></name><name><surname>Wilson</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>DrugBank 5.0: a major update to the drugbank database for 2018</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>D1074</fpage><lpage>D1082</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx1037</pub-id><pub-id pub-id-type="pmid">29126136</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wittinghofer</surname><given-names>A</given-names></name><name><surname>Pai</surname><given-names>EF</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>The structure of Ras protein: a model for a universal molecular switch</article-title><source>Trends in Biochemical Sciences</source><volume>16</volume><fpage>382</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1016/0968-0004(91)90156-p</pub-id><pub-id pub-id-type="pmid">1785141</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wittinghofer</surname><given-names>A</given-names></name><name><surname>Scheffzek</surname><given-names>K</given-names></name><name><surname>Ahmadian</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>The interaction of Ras with GTPase-activating proteins</article-title><source>FEBS Letters</source><volume>410</volume><fpage>63</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/s0014-5793(97)00321-9</pub-id><pub-id pub-id-type="pmid">9247124</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wittinghofer</surname><given-names>A</given-names></name><name><surname>Vetter</surname><given-names>IR</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Structure-function relationships of the G domain, a canonical switch motif</article-title><source>Annual Review of Biochemistry</source><volume>80</volume><fpage>943</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-062708-134043</pub-id><pub-id pub-id-type="pmid">21675921</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>A</given-names></name><name><surname>Lou</surname><given-names>D</given-names></name><name><surname>McCormick</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling</article-title><source>Cancer Discovery</source><volume>3</volume><fpage>112</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0231</pub-id><pub-id pub-id-type="pmid">23103856</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Vanommeslaeghe</surname><given-names>K</given-names></name><name><surname>MacKerell</surname><given-names>AD</given-names><suffix>Jr</suffix></name></person-group><year iso-8601-date="2012">2012</year><article-title>Extension of the charmm General force field to sulfonyl-containing compounds and its utility in biomolecular simulations</article-title><source>Journal of Computational Chemistry</source><volume>33</volume><fpage>2451</fpage><lpage>2468</lpage><pub-id pub-id-type="doi">10.1002/jcc.23067</pub-id><pub-id pub-id-type="pmid">22821581</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>R</given-names></name><name><surname>Hu</surname><given-names>Q</given-names></name><name><surname>Peacock</surname><given-names>H</given-names></name><name><surname>Peacock</surname><given-names>DM</given-names></name><name><surname>Dai</surname><given-names>S</given-names></name><name><surname>Shokat</surname><given-names>KM</given-names></name><name><surname>Suga</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>GTP-state-selective cyclic peptide ligands of K-Ras (G12D) block its interaction with Raf</article-title><source>ACS Central Science</source><volume>6</volume><fpage>1753</fpage><lpage>1761</lpage><pub-id pub-id-type="doi">10.1021/acscentsci.0c00514</pub-id><pub-id pub-id-type="pmid">33145412</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.79747.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cui</surname><given-names>Qiang</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05qwgg493</institution-id><institution>Boston University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.04.24.489309" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.04.24.489309"/></front-stub><body><p>This study employs extensive MD simulations to probe the effect of phosphorylation of a tyrosine residue on the conformational ensemble of Ras GTPase. The insights form the basis for a screen of small molecule(s) that disrupt interaction with its target Raf kinase, and predictions are tested experimentally. Overall, the integrated approach is of interest to a wide range of biochemists and protein scientists and could potentially be used to modulate the activities of other proteins.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.79747.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Cui</surname><given-names>Qiang</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05qwgg493</institution-id><institution>Boston University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Sugita</surname><given-names>Yuji</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01sjwvz98</institution-id><institution>RIKEN</institution></institution-wrap><country>Japan</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.04.24.489309">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.04.24.489309v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Inhibition of mutant RAS-RAF interaction by mimicking structural and dynamic properties of phosphorylated RAS&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by a Reviewing Editor and Jonathan Cooper as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Yuji Sugita (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>The most essential revisions that the reviewers have suggested concern statistical error analysis of the simulation results, and correction of the computed free energy profile in Figure 9. Essentially all reviewers expressed major concerns about the correctness of the computed PMF, in terms of both the qualitative trend and quantitative values.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Overall, I think the simulations have been conducted properly and analyzed carefully. However, I have two major questions.</p><p>1. Foremost, the results in Figure 9 are potentially very confusing. The free energy scale here is several hundreds of kcal/mol, which is clearly not physical for the conformational rearrangement of the SwI motif. Second, even at a qualitative level, the PMF is downhill in nature without any obvious barrier. This is also largely unexpected. Finally, the downhill nature is less clear with the bound ligand, which doesn't readily explain how the ligand facilitates the conformational rearrangement in SwI as the authors claim. I think the PSP method is interesting but needs to be explained and discussed much more carefully, in terms of both qualitative features and quantitative values of the results.</p><p>2. On Pg6, the authors commented on the level of hydration of the γ phosphate in various protein variants, and suggested that a higher level of hydration can explain the higher level of intrinsic GTPase activity. This correlation is not immediately obvious to me, as the enzymatic activity is often inversely correlated with the level of active site hydration since a higher hydration level likely leads to higher reorganization energy and therefore a higher activation free energy barrier.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>As I pointed out in the public review, I recommended the authors repeat the simulations a few times for improving the statistical significance and adding the errors. Also, I have several requests about the data presentations.</p><p>(1) In the distributions they showed in Figures (such as Figures 4C, 4D, 5A, 5B, and 5C), the curves are very smooth, lacking any noise. It seems to be unusual for me in MD simulations. I recommend the authors show the original data without smoothing, which is more natural for me (and readers).</p><p>(2) Clarification of structural figures is required. For instance, we can't see the green characters embedded in Figures 2E and 3B. Although the key residues are annotated in Figure 1A, I suggest the authors annotate key residues in other structural figures as well.</p><p>(3) PMF should be computed with enhanced sampling, such as umbrella sampling or metadynamics.</p><p>(4) More technical details are required in the Methods. Program package of MD simulation (Gromacs?) should be mentioned. I don't know which force field (AMBER of CHARMM, and which version) is used in the simulation.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>The authors need to address the issues given in the public review by:</p><p>• Increasing their data range (at least five independent simulations in total) and/or proving convincingly that the data they collected is robust and the observed structural and dynamical effects are real. The most convincing way to do so is to include ensemble means and respective error bars in all distribution plots.</p><p>• Clearly stating which system (WT; pY32; G12D) has been simulated and how often for how much time.</p><p>• Showing data on the convergence of their results, e.g., RMSD plots of the protein backbone over time for the simulations.</p><p>• Either remove the PMF data completely or search for the pathways present in the data set (see the given article Jäger et al., J. Chem. Mol. Model. 2022) and analyze trajectories according to pathways. Additionally: how many independent pulling simulations did the authors perform? How long were these simulations?</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for resubmitting your work entitled &quot;Inhibition of mutant RAS-RAF interaction by mimicking structural and dynamic properties of phosphorylated RAS&quot; for further consideration by <italic>eLife</italic>. Your revised article has been evaluated by Jonathan Cooper (Senior Editor) and a Reviewing Editor.</p><p>The manuscript has been substantially improved but there are some remaining issues that need to be addressed. In particular, as Reviewer #3 highlighted, it is important to clarify several technical details, especially concerning the PMF calculations.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>The authors significantly expanded the scope of the sampling in their simulations, especially the steered MD simulations. The results are more sound and generally support the mechanistic picture that emerged from the study of the effect of phosphorylation. I think the revision is appropriate for publication.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>In the revised manuscript, the authors addressed almost all the issues that I had been concerned about in the original one. In particular, a very large free-energy barrier in figure 9 was a big problem in the original manuscript. To resolve this, the authors added more &quot;pulling simulations&quot; to get converged the PMF as shown in the revised manuscript. Although this is a different approach than I suggested, the results are now reasonable and fine for me. I expect that this has involved their significant computations in additional molecular dynamics simulations and I appreciate their effort in the revisions.</p><p>I also suggested the authors to improve the methods section for telling the technical points more clearly. According to the modified sentences (highlighted in yellow), it looks now fine.</p><p>Overall, the revised manuscript has been improved greatly compared to the original submission. The authors satisfactorily addressed the questions and comments by reviewers.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>While the authors have addressed some of my concerns, not all points have been sufficiently addressed and need additional revisions:</p><p>• The distributions in Figures 2a,b; 3a; 4c,d; 5; 7 and most of the histograms in the SI still are missing error bars. Please do the following: Calculate distributions of distances or angles for each simulation separately. Then calculate the mean distributions as a function of distance/angle, as well as the respective standard error of the mean. Display the mean distributions as lines, and the standard error of the mean as a shaded area.</p><p>• Steered pulling: The PMF in Figure 9 looks much better now – too good for my experience, actually, as only 70 simulations were used as input for a 2nd cumulant expansion of the Jarzynski identity. And especially the error bars are incredibly small. I do not understand how the block averaging procedure mentioned in the text should work here. Usually, error estimation with the 2nd cumulant approximation is performed based on Jackknifing or bootstrapping – what do the respective errors look like when using this approach? What are the pulling rates employed? How was the &quot;pathway analysis&quot; performed? On what criteria were trajectories kept or discarded? And: The insight that different paths cause erroneous free energy estimates is not &quot;well known&quot;, as is currently described in the text, but rather new insight – please cite, e.g., Bray et al., J. Chem. Inf. Model. 2022, 62, 4591-4604. In general, I agree here with reviewer #2 who requested Umbrella Sampling calculations instead of the steered MD results given here.</p><p>• PCA: I do not find the answer to my question why only the first three eigenvectors were used convincingly. If the authors want to leave out the remaining eigenvectors that contribute the remaining 30% of cumulative eigenvalues, they need to provide evidence of why this is applicable. They could, e.g., plot free energies calculated from the simulation data along the eigenvectors and show for which eigenvectors the distributions are non-trivial, i.e., not following a normal distribution.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.79747.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>Overall, I think the simulations have been conducted properly and analyzed carefully. However, I have two major questions.</p><p>1. Foremost, the results in Figure 9 are potentially very confusing. The free energy scale here is several hundreds of kcal/mol, which is clearly not physical for the conformational rearrangement of the SwI motif. Second, even at a qualitative level, the PMF is downhill in nature without any obvious barrier. This is also largely unexpected. Finally, the downhill nature is less clear with the bound ligand, which doesn't readily explain how the ligand facilitates the conformational rearrangement in SwI as the authors claim. I think the PSP method is interesting but needs to be explained and discussed much more carefully, in terms of both qualitative features and quantitative values of the results.</p></disp-quote><p>We thank the reviewer for this comment. We have now increased the number of SMD simulations to 70 (from the 10 in the original submission) for each system. The pulling directions remain the same. We find that in the ligand-free form of Ras, 9 of these trajectories diverge from the intended path and are discarded from the analyses. In the ligand-bound form, all trajectories stay on-path. We can now clearly show two features of the ligand-free Ras: The SwI open form is ca. 3.5 kcal/mol lower in energy; however, there is a ca. 30 kcal/mol barrier to the transition in this case. In cerubidine-bound Ras, there is no barrier to opening the switch and the energy required to reach this state is ca. 10 kcal/mol. We note that the open form is no longer the lower energy state due to the presence of the nearby cerubidine.</p><disp-quote content-type="editor-comment"><p>2. On Pg6, the authors commented on the level of hydration of the γ phosphate in various protein variants, and suggested that a higher level of hydration can explain the higher level of intrinsic GTPase activity. This correlation is not immediately obvious to me, as the enzymatic activity is often inversely correlated with the level of active site hydration since a higher hydration level likely leads to higher reorganization energy and therefore a higher activation free energy barrier.</p></disp-quote><p>We would like to thank the reviewer for pointing this out. It has been shown that anchoring Y32 to the <sub>γ</sub>-phosphate contributes to the capturing of the catalytic waters that participate in intrinsic hydrolysis (Structural impact of GTP binding on downstream KRAS signaling; Chem. Sci.<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1039/2041-6539/2010">,</ext-link> 2020, 11, 9272-9289) by mediating a triple proton transfer step from the catalytic water-assisting water-Y32 to <sub>γ</sub>-phosphate. In the same study, the authors also showed that partial displacement of Q61 leads to opening-up of the catalytic pocket and destabilization of catalytic waters, thus impairing the intrinsic hydrolysis. Therefore, we agree with the reviewer that a higher level of hydration does not correlate with increased intrinsic GTPase activity of RAS. Bunda <italic>et al.,</italic> on the other hand, showed that phosphorylation of Y32 inhibits RAF binding, and promotes association of RAS with GAP hence promoting GTP hydrolysis. We showed that Switch I and II undergo conformational rearrangements upon phosphorylation. Considering the fact that GAP binding involves interaction with Switch I and II of RAS, it can be said that phosphorylation helps rearrangement of the nucleotide-binding pocket of RAS, hence modulating GTPase activity of the protein by mediating its interaction with GAP. The following sentence has therefore been removed in the revised version:</p><p>Line 145-146 of the original MS: thus, presumably, modulating intrinsic GTPase activity of the protein, and revised as follows:</p><p>“Considering rearrangements occurring around the nucleotide-binding pocket and that GAP binding involves interaction with both Switches I and II, it can be said that phosphorylation helps rearrangement of the nucleotide-binding pocket of RAS, hence modulating the GTPase activity of the protein by mediating its interaction with GAP” (Page: 5; Lines:150-154).</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>As I pointed out in the public review, I recommended the authors repeat the simulations a few times for improving the statistical significance and adding the errors. Also, I have several requests about the data presentations.</p></disp-quote><p>We thank the reviewer for his suggestion, and we apologize for the lack of statistical significance information in the original submission. We repeated the simulations four times for each system studied and provided respective timelines as figure supplements in the revised version. We provided the standard errors in the figure captions.</p><disp-quote content-type="editor-comment"><p>(1) In the distributions they showed in Figures (such as Figures 4C, 4D, 5A, 5B, and 5C), the curves are very smooth, lacking any noise. It seems to be unusual for me in MD simulations. I recommend the authors show the original data without smoothing, which is more natural for me (and readers).</p></disp-quote><p>As the reviewer suggested, we provided the original data pertaining to Figures 4C, 4D, 5A, 5B, and 5C in Figure 4—figure supplement 2 &amp; 3, and Figure 5—figure supplement 1 of the revised version and keep the smoothed ones in the main text.</p><disp-quote content-type="editor-comment"><p>(2) Clarification of structural figures is required. For instance, we can't see the green characters embedded in Figures 2E and 3B. Although the key residues are annotated in Figure 1A, I suggest the authors annotate key residues in other structural figures as well.</p></disp-quote><p>We have now annotated key residues in Figures 2C, 2D, 2E, and 3B in the revised version. Also, we have clarified the characters mentioned by the reviewer in revised Figures 2E and 3B.</p><disp-quote content-type="editor-comment"><p>(3) PMF should be computed with enhanced sampling, such as umbrella sampling or metadynamics.</p></disp-quote><p>Considering the options pointed out by all three reviewers regarding the sampling of the states to calculate the PMF, we chose to increase the number of samples from 10 to 70 for each system. The pulling directions remain the same. We find that in the ligand-free form of Ras, 9 of these trajectories diverge from the intended path and are discarded from the analyses. In the ligand-bound form, all trajectories stay on-path. We can now clearly show two features of the ligand-free Ras: The SwI open form is ca. 3.5 kcal/mol lower in energy; however, there is a ca. 30 kcal/mol barrier to the transition in this case. In cerubidine-bound Ras, there is no barrier to opening the switch and the energy required to reach this state is ca. 10 kcal/mol. We note that the open form is no longer the lower energy state due to the presence of the nearby cerubidine.</p><disp-quote content-type="editor-comment"><p>(4) More technical details are required in the Methods. Program package of MD simulation (Gromacs?) should be mentioned. I don't know which force field (AMBER of CHARMM, and which version) is used in the simulation.</p></disp-quote><p>We would like to thank the reviewer to point out the ambiguity regarding technical details. We mentioned the full name of the software package in the original text. Yet, the abbreviation of the software was not written therein. To clarify the technical details, we added the abbreviation of the simulation package along with its version in the revised version of the main text —the CUDA version of NAMD. We would like to point out however that the force fields used to model protein and water were given in the original manuscript. We used CHARMM36m and TIP3P to model protein/nucleotide and water, respectively (page 15 in the current version).</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>The authors need to address the issues given in the public review by:</p><p>• Increasing their data range (at least five independent simulations in total) and/or proving convincingly that the data they collected is robust and the observed structural and dynamical effects are real. The most convincing way to do so is to include ensemble means and respective error bars in all distribution plots.</p></disp-quote><p>During the revision period, we performed additional simulations to have four replicates, each of which was about 1 <sub>µ</sub>s, per system. For ligand-bound RAS systems, we ran the simulations until Switch I was displaced from the nucleotide-binding pocket and extended it for an additional <italic>ca</italic>. 200-300 ns to check if it comes back to its original position. Respective timeline plots of the replicates of both ligand-bound and non-liganded systems were provided as the figure supplements in the revised manuscript. We also reported error values in the caption of corresponding figures in the main text. Information regarding simulation times was provided in the methods section. Also, we revised the total simulation times for each ligand-bound RAS system in the SI of the revised manuscript.</p><p>Importantly, we observed similar behavior in each replicate of the systems; we, therefore, conclude that the results presented in the original manuscript are reproducible.</p><disp-quote content-type="editor-comment"><p>• Clearly stating which system (WT; pY32; G12D) has been simulated and how often for how much time.</p></disp-quote><p>As explained above, we performed 4 replicates of simulations for HRAS<sup>WT</sup>, HRAS<sup>G12D,</sup> and HRAS<sup>pY32</sup>, each of which is about 1µs. Corresponding information was provided in detail in the methods section of the revised manuscript.</p><disp-quote content-type="editor-comment"><p>• Showing data on the convergence of their results, e.g., RMSD plots of the protein backbone over time for the simulations.</p></disp-quote><p>The backbone RMSD of the studied systems were provided in the response letter (See Figure 1 (vide supra)).</p><disp-quote content-type="editor-comment"><p>• Either remove the PMF data completely or search for the pathways present in the data set (see the given article Jäger et al., J. Chem. Mol. Model. 2022) and analyze trajectories according to pathways. Additionally: how many independent pulling simulations did the authors perform? How long were these simulations?</p></disp-quote><p>We have increased the number of simulations in the data set from 10 to 70 and we have analyzed the trajectories according to the pathways as suggested by the referee. The information on the length of the simulations, data recording and processing are now provided in more detail on page 18.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><disp-quote content-type="editor-comment"><p>The manuscript has been substantially improved but there are some remaining issues that need to be addressed. In particular, as Reviewer #3 highlighted, it is important to clarify several technical details, especially concerning the PMF calculations.</p><p>Reviewer #3 (Recommendations for the authors):</p><p>While the authors have addressed some of my concerns, not all points have been sufficiently addressed and need additional revisions:</p><p>• The distributions in Figures 2a,b; 3a; 4c,d; 5; 7 and most of the histograms in the SI still are missing error bars. Please do the following: Calculate distributions of distances or angles for each simulation separately. Then calculate the mean distributions as a function of distance/angle, as well as the respective standard error of the mean. Display the mean distributions as lines, and the standard error of the mean as a shaded area.</p></disp-quote><p>We revised the corresponding histograms in the way the reviewer explained and presented them in the new version of the main text and the supplementary file.</p><disp-quote content-type="editor-comment"><p>• Steered pulling: The PMF in Figure 9 looks much better now – too good for my experience, actually, as only 70 simulations were used as input for a 2nd cumulant expansion of the Jarzynski identity. And especially the error bars are incredibly small. I do not understand how the block averaging procedure mentioned in the text should work here. Usually, error estimation with the 2nd cumulant approximation is performed based on Jackknifing or bootstrapping – what do the respective errors look like when using this approach? What are the pulling rates employed? How was the &quot;pathway analysis&quot; performed? On what criteria were trajectories kept or discarded? And: The insight that different paths cause erroneous free energy estimates is not &quot;well known&quot;, as is currently described in the text, but rather new insight – please cite, e.g., Bray et al., J. Chem. Inf. Model. 2022, 62, 4591-4604. In general, I agree here with reviewer #2 who requested Umbrella Sampling calculations instead of the steered MD results given here.</p></disp-quote><p>In fact, the block averaging method was referenced in the first SMD paper to be used for error calculation: https://aip.scitation.org/doi/10.1063/1.1590311<ext-link ext-link-type="uri" xlink:href="https://aip.scitation.org/doi/10.1063/1.1590311">.</ext-link> As per reviewer`s request, we also estimated the error via bootstrapping method using 500 iterations, retaining 80% of the data in each calculation. The obtained profile is provided in <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>. We also referenced this paper mentioned in the revised version and included the PMF profile along with the errors calculated by bootstrapping.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><title>PMF profiles obtained by SMD experiments.</title><p>The errors are calculated by both block averaging (left) and bootstrapping (right).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79747-sa2-fig1-v3.tif"/></fig><disp-quote content-type="editor-comment"><p>What are the pulling rates employed?</p></disp-quote><p>This information was already provided in the manuscript (page 18, line 504-512);</p><p>The set of external poses were imposed to the Cαα atom of Y32, where the constant velocity and spring constant were adjusted to 0.03 Å ps<sup>-1</sup> and 90 kcal mol<sup>-Å-2,</sup> respectively. Moreover, the Cαα atoms of L23 and R149 residues were fixed along the pulling direction so as to prevent dislocation and rotation on the structure.</p><disp-quote content-type="editor-comment"><p>How was the &quot;pathway analysis&quot; performed? On what criteria were trajectories kept or discarded?</p></disp-quote><p>Herein, we present <xref ref-type="fig" rid="sa2fig2">Author response image 2</xref> to show the pathway that the pulled atom followed in each case. The off-pathway trajectories can be directly seen from these figures; in particular, they all followed the same pathway with a narrow range when the ligand is bound. In the unliganded one, we now discard 7 trajectories, for the seven that stay away from the bundle. The two green dots that stay with the bundle are now included in the PMF calculation, with no difference in the final PMF profile.</p><fig id="sa2fig2" position="float"><label>Author response image 2.</label><caption><title>The pathway analysis of SMD simulations.</title><p>The displacement of the pulled atom, which is shown in green color, is shown throughout the 70 SMD trajectories in both ligand and ligand-free states. The protein is shown in new cartoon representation and colored according to the respective secondary structures. The trajectories excluded are shown in red while those included in green. The protein is aligned using all the regions except the loop.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79747-sa2-fig2-v3.tif"/></fig><disp-quote content-type="editor-comment"><p>In general, I agree here with reviewer #2 who requested Umbrella Sampling calculations instead of the steered MD results given here.</p></disp-quote><p>The pulling experiments support our claim and are not included to make a quantitative assessment of the observations. We therefore chose not to do the umbrella sampling calculations. Reviewer 2 is now satisfied with the findings; as they state, these have indeed involved significant computational resources.</p><disp-quote content-type="editor-comment"><p>• PCA: I do not find the answer to my question why only the first three eigenvectors were used convincingly. If the authors want to leave out the remaining eigenvectors that contribute the remaining 30% of cumulative eigenvalues, they need to provide evidence of why this is applicable. They could, e.g., plot free energies calculated from the simulation data along the eigenvectors and show for which eigenvectors the distributions are non-trivial, i.e., not following a normal distribution.</p></disp-quote><p>As a correction, we had presented first five eigenvectors in the revised version of the manuscript. As per reviewer`s request, we, hereby, present the first 28 eigenvectors that contribute to the 80% of the overall dynamics. As can be seen in <xref ref-type="fig" rid="sa2fig3">Author response image 3</xref>, we observed peaks in the same regions, which were captured by the first five eigenvectors, using less dominant eigenvectors. Having this said, it is also important to mention we observed additional peaks for the region that was spanned by residues 100-150 yet with lower contribution to the dynamics. The hypothesis we proposed in the manuscript was to check if it was possible to prevent interaction between RAS and RAF by distorting the Switch I region. By means of PRS calculations, we showed that the optimum pathway to distort it would be the distortion of the region itself as it gave higher overlapping coefficient. The region spanned by residues 100-150 did not emerge as the one that could be used for a target site. Moreover, the possibility that a conformational change can be described by a few normal modes was also shown in the study of Petrone and Pande (Petrone P, Pande VS. Can conformational change be described by only a few normal modes? Biophysical journal. 2006; 90(5):1583–1593), whereby 50% cutoff was used to do all the relevant discussions. We therefore did not further modify this part in the manuscript. This paper is also referenced in the current version of the manuscript (Page:6, line 181).</p><fig id="sa2fig3" position="float"><label>Author response image 3.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79747-sa2-fig3-v3.tif"/></fig></body></sub-article></article>